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Tick-borne encephalitis virus (TBEV) is a human pathogen of the genus Flavivirus, which 
includes closely related mosquito-borne viruses like Yellow fever (YF), West Nile (WN) and 
Dengue fever (DEN) viruses. Due to antigenic cross-reactivity the serological diagnosis is 
difficult, especially when whole virus is used as antigen. Moreover, an understanding of the 
frequencies of antigen specific memory B cells and their relationship with the antibodies in 
serum serological memory is likely to be critical to evaluate the long-term protective efficacy 
of vaccine. For he purpose to overcome the existing test-limitations, domain III of the 
envelope protein (ED3) from TBEV and WNV were expressed in E. coli to evaluate their use 
as antigen in ELISA using predefined sera positive for either TBEV or WNV and sera tested 
negative for flaviviruses. An Enzyme-Linked ImmunoSpot (ELISPOT) assay is used for 
detection of activated TBE-specific antibody secreting B cells (ASCs) in TBE vaccinated 
individuals. This ELISPOT-based technique follows same basic principles as ELISA, but it 
enables directly to identify antibody secreting progeny of memory B cells rather than only 
measuring the accumulated antibody that they produce. The results demonstrated that all 
sera from TBEV-infected patients were positive in rED3-based ELISA. This ELISA result was 
consistent with that displayed with commercial kit. In addition, ELISA using recombinant 
antigens showed no cross-reactivity against sera from WNV or DENV infected patients. 
Therefore, rED3 used in this study demonstrated significant potential for the development of 
anti-TBEV ELISA diagnostic assay for detection of specific IgG to TBEV in serum specimens. 
TBEV-rED3 specific ASCs were detected in previously vaccinated individuals with frequency 
of ASCs ranging 0.016-0.188% per total IgG ASCs. No statistical significant correlation 
between frequency of antigen specific ASCs and antibodies level in serum was found. In 
addition, these study findings also indicated TBE specific memory B cells and neutralizing 
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1.1. Tick borne encephalitis virus (TBEV):  Epidemi ology and Structure 
Tick-borne encephalitis virus (TBEV) is causing severe illness including infection of 
the central nervous system. It represents a major health problem in Central and Eastern 
European countries. Between 1990 and 2009 a total of 169,937 cases of TBE were recorded 
in Europe, i.e. an annual average of 8497 cases. Of these, 2815 cases (33.1%) occurred in 
Central and Eastern Europe excluding Russia (Heinz and Kunz, 2004; Kollaritsch et al., 
2011; Suss, 2011). The reported cases over the last three decades correspond to an 
increase of 317.8% in Europe including Russia and 193.2% in Europe without Russia (Suss, 
2011; Zavadska et al., 2013). As TBEV is transmitted by ticks, the reasons for the increase of 
TBE cases may be in association with the exceptional weather conditions in Central Europe. 
A continuous increase of the average temperatures and of the precipitations lead to 
increased humidity and improve the living conditions of ticks as a humidity >85% and 
temperature 6°C to 7°C by wild winter (Suss, 2008). These climate changes are affecting 
vector biology and pathogen transmission (Gray et al., 2009). 
TBEV belongs to genus Flavivirus that comprises over 70 viruses, of which many are 
important human pathogens (Lindenbach et al., 2007). Although, some flaviviruses have no 
known vector, most members are either transmitted by mosquitoes e.g. WNV, DENV or ticks 
e.g. TBEV (Chambers et al., 1990). 
Based on moderate differences in their nucleotide sequences and “signatures” on 
protein level, TBE viruses are grouped into three closely related subtypes: a central 
European subtype (TBEV-Eur), a Far-Eastern subtype (TBEV-FE) and a Siberian subtype 
(TBEV-Sib) (Ecker et al., 1999; Mukhopadhyay et al., 2005).  
The virions of TBEV are spherical particles with approximately 50-60 nm in diameter 
(Slavik et al., 1967). Like all flaviviruses, the genome is a single-stranded positive-sense 
RNA genome of approximately 11 kb in length and has a 5’ type-1 cap structure 
(m7G5’ppp5’A) but no  3’ polyadenylated tail (Chambers et al., 1990; Lindenbach et al., 2007; 
Linquist et al., 2008). The viral RNA contains a single open reading frame (ORF) that is 
flanked by 5’ and 3’ untranslated regions (UTRs) (Figure 1). The single ORF encodes a 
polyprotein that is cleaved co- and post-translationally by viral and cellular proteases into 
three structural and seven nonstructural proteins. While the structural proteins, the capsid 
(C), pre-membrane/membrane (prM/M), and the major envelope glycoprotein (E) are parts of 
the virion the non-structural proteins NS1 (glycoprotein), NS2A, NS2B (protease component), 
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NS3 (protease, helicase and NTPase activity), NS4A, NS4B and NS5 (RNA-dependent 
polymerase) play major role in virus replication and modulation of immune response 




Figure 1. The schematic drawing of a Flavivirus full-length genome (Lindenbach et al., 2007) 
 
1.2. Structure and function of virus envelope prote in 
The envelope protein of flaviviruses, E protein, carries the receptor-binding site for 
attachment and comprises the fusion peptide, which mediates uncoating by fusion of viral 
and cellular membranes. Additionally, the E protein comprises the major antigen and induces 
formation of protective antibodies (Chambers et al, 1990; Pletnev, 1986). Early studies used 
mAbs to identify the antigenic structure of the flavivirus E protein (Heinz et al., 1983; Roehrig 
et al., 2003). The atomic structure of E has been solved for TBEV, DENV-2, DENV-3, WNV 
and JEV by X-ray crystallography of recombinant proteins comprising the first approximately 
400 residues of E, referred to as the soluble E ectodomain (sE) (Kanai et al., 2006; Modis et 
al., 2005). The E glycoprotein forms a head-to-tail homodimer and is composed of three 
distinct domains, referred to as ED1, ED2 and ED3 (Figure 2). ED1 is the central domain and 
links domain ED2 and ED3 (White et al., 2003). ED2 is called the dimerization domain, as it 
appears to be the principal region of interaction between monomers in E protein dimers on 




Figure 2. Crystal structure of the E protein domains (Mukherjee et al., 2006) 
 
ED3 contains the receptor-binding site, and is the putative receptor-binding domain 
(Erb et al., 2010; Lee and Lobigs, 2002). ED3 is highly immunogenic with a number of 
virus-neutralizing antibody sites mapped to ED3 (Beasley et al., 2002; Crill et al., 2001; 
Thullier et al., 2001). In particular, ED3 contains many linear epitopes as determined using 
monoclonal antibodies (White et al., 2003). Correct presentation of ED3 epitopes was 
originally shown to depend on the single disulfide bridge that ED3 contains (Mason et al., 
1989; Winkler et al., 1987). Many studies have verified the antigenic and biological 
authenticity of recombinant ED3 (rED3) from several different flaviviruses (Beasley et al., 
2004; Bhardwaj et al., 2001). Some of these studies also demonstrate the application of ED3 
for the specific serological diagnosis of flavivirus infection, like WNV infections (Davis et al., 
2004; Wang et al., 2001) or DENV infections (Wahala et al., 2009). In animal model, mice 
immunized with virus specific ED3 resulted in high titres of neutralizing antibodies and thus 
protection against lethal infectious doses of WNV (Martina et al., 2008; Spohn et al., 2010), 
JEV (Wu et al., 2003) and DENV-2 (Simmons et al., 1998), respectively. Additionally, cross 
protection was observed in mice immunized with ED3 of JEV against lethal WNV infection 
(Li et al., 2011). NMR (Nuclear magnetic resonance)-derived solution structures of ED3s of 
the DENV-2 (Huang et al., 2008), DENV-4 (Volk et al., 2007), JEV (Wu et al., 2003), WNV 
(Volk et al., 2004), Omsk hemorrhagic fever virus (Volk et al., 2006), and Langat virus 
(Mukherjee et al., 2006) have been determined based on work with recombinant ED3s and 
indicate an overall similarity in structural fold. NMR structures are also very similar to the 
ED3 structures obtained by X-ray crystallography of full E protein ectodomains (Kanai et al., 




1.3. Clinical Symptom and immune response to TBEV 
Serological surveys suggest that 72-87% of human TBE virus infections develop a 
typical biphasic course of disease with “flu-like illness” (Holzmann, 2003; Kaiser and 
Holzmann, 2000). The incubation period is generally 7–14 days and during a typical biphasic 
infection, symptoms during the initial short febrile period (Figure 3) can include fatigue, 
headache and pain in the neck, shoulders and lower back, accompanied by high fever and 
vomiting (Gritsun et al., 2003). This is often followed by an asymptomatic period lasting 2–10 
days and if the disease progresses to neurological involvement, this leads to the second 
phase, characterized by acute central nervous system (CNS) symptoms with a high fever. 
CNS infection can manifest in the meninges, the brain parenchyma, the spinal cord and/or 
the nerve roots. Thus the second phase of disease is characterized by encephalitic 
symptoms in 45–56% of patients (Haglund and Gunther, 2003) with high fever (often >39°C) 
accompanied by signs of meningitis, encephalitis, or radiculitis or mixed neurological forms 
characterized by severe headache, stiffness of the neck, nausea, vomiting and vertigo. 
Cerebellar signs and symptoms typically including ataxia dominate encephalitis caused by 
TBEV (Kaiser and Holzmann, 2000). However, TBEV may induce a variety of neurological 
symptoms such as disturbed consciousness, convulsions, speech disorder, and vertigo. 
Affection of cranial nerves with associated symptoms may occur as well.   
IgM antibodies appear during early stage of the disease, and persist for at least 6 
weeks (up to several months), while IgG antibodies tend to appear a little later and to reach 
maximum concentration in the convalescent phase, around 6 weeks after onset of the 
disease. IgG antibodies confer immunity and persist for lifetime and provide a level of 












Figure 3.  Immune response in TBE with development of specific antibodies (ab) in serum and 
cerebrospinal fluid (CSF) (Holzmann, 2003) 
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1.4. Vaccination and humoral immune response 
The goal of vaccination is to stimulate the primary adaptive response to a specific 
agent including the development of immunologic memory so that upon natural exposure to 
the same agent, the adaptive immune system will be primed to deal effectively and swiftly 
with the pathogen.  
Active immunization is currently the only option for prophylaxis against TBE and is 
highly recommended for all persons in high-risk areas when pursuing outdoor activities. 
Encepur® and TBE-Immun®, the two vaccines that are manufactured in Western Europe, 
are based on cell cultured and inactivated TBEV, adjuvanted to aluminum hydroxide (Zent 
and Broker, 2005). Both vaccines are widely used in TBE-endemic EU-countries and have 
been proved to be highly effective (Barrett et al., 2003; Zent et al., 2003). Two Russian 
vaccines are on the market: TBE Moscow Vaccine® and EnceVir® (Leonova and Pavlenko, 
2009; Vorob'eva et al., 2007). Like the Western TBE vaccines, they are based on primary cell 
culture of chicken fibroblasts and are using aluminum hydroxide as adjuvant (Leonova and 
Pavlenko, 2009). The Western vaccines use strains of European (TBEV-Eu) subtype 
(Neudörfl and K23) which are almost identical in amino acid sequence, while the Russian 
vaccines are derived from the Sofjin and 205 strains, both belonging to the Far Eastern 
(TBEV-FE) subtype (Leonova and Pavlenko, 2009; Vorob'eva et al., 2007). However, the 
degree of variation between TBEV subtypes is low with a maximum difference of 5.6% at the 
amino acid level (Ecker et al., 1999; Lindquist and Vapalahti, 2008). Both Western vaccines 
show cross protection in mice against the other TBEV subtypes, and vice versa (Holzmann 
et al., 1992; Leonova et al., 2007).  
The conventional vaccination schedule is 0, 21 days to 3 months, and 9-12 months 
with regularly boosters after 3 years. Several studies have investigated the persistence of 
protective immunity following vaccination using ELISA for serum antibody titre determination 
or neutralisation tests and found a longer protection than originally assumed (Holzmann et 
al., 1996; Rendi-Wagner et al., 2004; Rendi-Wagner et al., 2007). Thus, requirements of 
booster immunizations and their time interval are questioned regularly.  
After natural infection or vaccination, naive antigen-specific B cells bind the soluble 
antigen by their B-cell receptor (BCR), internalize the complex, degrade the antigen into 
peptide pieces in endosomal compartments, and present those pieces in complex with 
MHC II molecules to T cells (Parham, 2005; Tulp et al., 1994). Are the presented antigens 
recognized by CD4+ T cells it comes to mutual activation steps between the B and T cells 
and a primary focus in which B cells proliferate and differentiate to IgM-secreting plasma 
cells is formed. 3-4 days after primary immunization or infection, antigen-specific IgM 
antibodies are detected in the serum. These molecules have only a low affinity to their 
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antigen (Berek, 1992). The short-lived IgM secreting plasma cells can’t maintain long time 
immunity. Some of these proliferating B cells, in cognate interaction with T cells, migrate into 
primary follicles to form a germinal centre (GC) (Liu and Arpin, 1997). At the GC, proliferating 
B cells undergo massive proliferation, isotype switching to other Ig classes (IgG, IgE, IgA), 
somatic hypermutation and affinity maturation (Parham, 2005). In the second phase of the 
primary immune response plasma cells producing high-affinity IgG molecules and long-lived 
memory B cells with high BCR-affinity to the specific antigen are formed (Kalia et al., 2006) 
(Figure 4).  
Prolonged antibody production lasting for years after infection or vaccination provides 
the first line of defense against pathogens and is the key to humoral protection. 
Immunological memory in the B-cell compartment consists of two distinct cell types: Memory 
B cells (MBCs) and Long-lived plasma cells (LLPCs). While LLPCs mainly reside in the bone 
marrow and continuously produce large amounts of Abs without the need for re-stimulation 
by antigen (Radbruch et al., 2006; Tangye, 2011) the MBCs are re-activated by antigen 
contact (Gray, 1993). MBCs express a high-affinity BCR and are mainly localized in proximity 
to secondary lymphoid organs and especially in the spleen (Liu et al., 1989; 
Mamani-Matsuda et al., 2008) at much higher frequencies relative to naïve B cells specific 
for the same antigen. MBCs express a reduced activation threshold coupled with an 
increased expression of co-stimulatory molecules and activation markers compared to naïve 
B cells and they can therefore quickly react to antigen challenge. Upon re-encounter with the 
cognate antigen MBCs respond by proliferating and differentiating into short-lived 
antibody-secreting cells (ASCs) that produce large amounts of high affinity Abs (mainly IgG)  
(Ahmed and Gray, 1996; Rajewsky, 1996). 
 
Figure 4. Differentiation of memory B and T cells (modified, Kalia et al., 2006). Ag: antigen; PC: 





While antibody titres decrease over the years memory B-cells might be still present. 
Thus, for analysis of immune status of vaccinees the examination of the presence or 
absence of memory B cells might be of interest. A technique that allows the investigation of 
immunological memory of the humoral immune response is the B-cell ELISPOT.  
The B-cell ELISPOT was first described in 1983 (Czerkinsky et al., 1983) and has 
been an important method for the detection of IgG-producing B cells. Memory B cells require 
pre-stimulation in order to differentiate into detectable antibody secreting cells (ASCs). 
Various methods have previously been described for inducing the differentiation of human 
memory B cells. These methods involve the culture of peripheral blood mononuclear cells 
(PBMCs) or purified B cells for 5 to 6 days in the presence of polyclonal stimuli and 
cytokines, such as Staphylococcus aureus Cowan I (SAC) and interleukin (IL)-2 (Kelly et 
al., 2006), pokeweed mitogen (PWM), unmethylated CpG oligodeoxynucleotides (CpG ODN) 
and SAC (Crotty et al., 2004), CD40L transfected CDw32L mouse fibroblasts plus IL-2 and 
IL-10 (Tuaillon et al., 2006), CpG and IL-15 (Bernasconi et al., 2002) or 
PWM, Staphylococcus aureus lysate, IL-2, IL-10 and phosphorothioated CpG ODN 
(Bussmann et al., 2010). Recently, evaluated methods for the activation of memory B cells 
and found that using the TLR7/TLR8 agonist R848 plus IL-2 was more efficient compared to 
PWM, CpG and SAC (Jahnmatz et al., 2013; Pinna et al., 2009; Walsh et al., 2013). While, 
interferon-γ ELISPOT assay relies on the visualization of cytokine secretion by individual T 
cells following in vitro stimulation with antigen and does not require in vitro expansion of 
specific T cells before testing (Yang et al., 2000).  
Nevertheless, data exist insufficiently which role memory B cells play for long-term immunity 
in humans e.g. after vaccinations and whether immunity is more reflected by the antibody 












2. Objectives of this work 
Tick-borne encephalitis virus (TBEV) is the most important tick-transmitted 
neurological disease in Central and Eastern European countries and in Russia. Due to 
antigenic cross-reactivity between TBE and other flaviviruses the serological diagnosis is 
difficult, especially when whole virus is used as antigen. Domain III of the E protein (ED3) is 
highly antigenic, and produced antibodies are highly neutralizing and specific for the different 
flaviviruses. 
Thus, this thesis aimed the establishment of a recombinant protein based ELISA and of a 
memory B cell assay for analysis of specific antiviral immunity after vaccination. In detail this 
included the following two objectives. 
 
2.1. Expression and purification of recombinant env elope protein domain 3 (rED3) 
and verification of its application as antigen in E LISA for TBEV diagnosis. 
The aim of this subproject is to express domain III of the envelope protein (ED3) from 
TBEV and WNV in E. coli to evaluate their use as antigen in ELISA for specific TBEV and 
WNV diagnosis. This includes cloning of expression vectors using E. coli as expression 
system and subsequently expression and purification of rED3 with N-terminal MBP and 
C-terminal histidine tag by affinity chromatography. Purified rED3 was tested for its 
applicability as ELISA antigen using predefined sera positive for either TBEV or WNV and 
sera tested negative for flaviviruses.  
 
2.2. Establishment of a memory B cells assay using rED3 for determination of 
frequency of rED3 specific antibody-secreting cells  (ASCs) in individuals 
vaccinated against TBE.  
 Memory B cells are the principal determinant of long-term humoral immunity elicited 
by vaccination. Thus, assessing quantitative parameters other than serum antibody levels 
after immunisation, such as memory B-cells may provide helpful insight into major 
determinants of persistent immunity. For this purpose, PBMCs were isolated from blood 
donors with different vaccination history. Antigen specific B memory cells were stimulated to 
proliferate and differentiate into antibody secreting cells (ASCs) and were finally quantified 
using an Enzyme-Linked Immunospot (ELISPOT) assay. Plasma of donors was analysed 
using ELISA and neutralisation test.  
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CHAPTER 2. MATERIALS AND METHODS 
 
2.1. Materials 
Table 1. Cell lines  
Cell line Kind of cell ATCC-Nr. Source 
Vero-Cells 
African green monkey 
kidney cells 
CCL-81 
Institute of Virology, 
Leipzig University  
PS-cells porcine kidney cells   not available RKI, Berlin 
 
Table 2. Bacteria strains 
Bacteria strain Genotype Source 
E. coli K12 DH5α 
huA2 ∆(argF-lacZ)U169 phoA glnV44 
Φ80 ∆(lacZ)M15 gyrA96 recA1 relA1 
endA1 thi-1 hsdR17 
Institute of Virology, 
Leipzig University 
E. coli BL21 (DE 3) 
fhuA2 [lon] ompT gal (λ DE3) [dcm] 
∆hsdS 
λ DE3 = λ sBamHIo ∆EcoRI-B 
int::(lacI::PlacUV5::T7 gene1) i21 
∆nin5 
Institute of Virology, 
Leipzig University 
 
Table 3. Plasmids 
Name Characteristics 
pMAL-c2x 
Empty expression plasmid for expression of cloned fragments 
as MBP fusion proteins in bacteria (New England Biolabs)  
WNV-D3pMAlTag2  
Bacterial expression plasmid for expression of WNV ED3 as 
MBP fusion protein with C-terminal histidine tag, provided by 







Table 4. Virus strains 
Type strain Accession number Source 
WNV 





TBEV Hypr 9BMP U39292.1 
F.X. Heinz and C. 
Mandl/Vienna 
 
Table 5.  Kits 
Name Source Order number 
Big Dye® Terminator v1.1 Cycle 
Sequencing Kit 
Applied Biosystems 4337450 
Bio Rad Protein Assay Bio-Rad 500-0006 
Nucleospin® Plasmid Machery-Nagel 740588.250 
QIAprep® Spin Miniprep Kit Qiagen 72106 
ELISpotPLUS for Human IgG Kit  Mabtech 3850-2AW-Plus 





QIAquick Gel Extraction Kit Qiagen 28704 
recomWell FSME/TBE Virus IgG Mikrogen 6504 
 
Table 6. Standards 
Name Source Order number 
Gene Ruler 1 kb DNA-Ladder  Fermentas SM0311 
Gene Ruler 50 bp DNA-Ladder Fermentas SM0371 
50 bp DNA-Ladder New England Biolabs N0467G 
Gene Ruler LR DNA-Ladder Fermentas SM1191 
Page Ruler Prestained Protein 
Ladder 
Fermentas SM0671 




Table 7.  Enzymes 
Name Source Order Number 
Platinum-Taq-Polymerase Invitrogen Life Technologies 10966034 
PfuUltra™ II Fusion HS DNA 
Polymerase 
Stratagene 600670 
Restriction enzymes + buffers Fermentas  
T4 DNA-Ligase ( 5 Weiss U/µl)  Fermentas EL0331 
 
Table 8.  Antibodies 
Name Source 
Mouse-anti-(His)6-Tag (monoclonal,  
unconjugated); 0.2 mg/ml 
Dianova (Dia900) 
Rabbit anti-human IgG (HRP conjugated) Dako Cytomation (P0214) 
Rabbit-anti-mouse immunglobuline 
(HRP-conjugated); 1.3 g/l 
Dako Cytomation (P0260) 
 
Table 9. Chemicals and reagents 
Name Source Order number 
Acetic acid Roth 3738 
Acetone Roth/Applichem 9372 / A1582 
Acrylamide (Rotiphorese® Gel 30) Roth 3029 
Agarose: SeaKem®LEAgarose Biozym 840004 
Agar-Agar Roth  5210 
Ammonium persulfate (APS) AppliChem A2941 
Ampicillin sodium salt Roth K029.1 
Amylose resin NEB E8021S 
Aqua ad injectabilia (dH2OB) Braun PZN3113087 
Bovine serum albumine (BSA) Sigma A4503 
Bromphenol blue Fluka 18040 
dNTP-Set (ATP, CTP, GTP TTP each with 
100 mM) 
Fermentas R0186 
Citric acid Roth 1818 
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Name Source Order number 




1,4-Dithiothreitol (DTT) AppliChem A1101 
DMEM (+4500 mg/l, +Glutamax™I, -Pyruvat) Gibco  61965 
Ethanol absolut J.T.Baker 8228 
Ethidiumbromide Sigma E8751 
Ethylenediaminetetraacetic acid(EDTA) Roth 8043 
Fetal Calf Serum (FCS) Biochrom S0115/0446K 
Formaldehyde (37%) Roth 4979 
D-(+)-Glucose Roth/AppliChem X997 / A3594 
L-Glutamine (200 mM) Gibco 25030 
Glycine Roth 3790 





HPLC-Water Roth A511 
Hydrogen peroxide (30%, H2O2) Sigma 216763 
Hydrochloric acid (37%ig; HCl) Applichem  A0659 
Imidazole AppliChem A3635 
Isopropanol (2-Propanol) J.T.Baker 8067 
Loading Dye (6x) Fermentas R0611 
Luminol Sodium Salt Sigma A4685 
Low-fat milk powder Vitalia  
Isopropyl -β- D- thiogalactopyranosid (IPTG) Applichem A1008 
D-(+)-Maltose Roth 8951.1 
MEM NEAA (100x) Gibco 11140 
Methanol Roth CP43 
Neutral red Merck 1.01369.0025 
Ni-NTA Agarose Qiagen 30210 
PBS 10x (without Ca2+ and Mg2+) Gibco  70013 
Pen/Strep (10000 U/ml Penicillin, 
10000 µg/ml Streptomycin) 
Gibco 15140 
Peptone  Roth 8986 
Potassium acetate (CH3COOK) Roth T874 
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Name Source Order number 
Potassium dihydrogen phosphate (KH2PO4) AppliChem A2946 
di-potassium hydrogen phosphate (K2HPO4) Roth 687 
Potassium chloride (KCl) AppliChem A2939 
Potassium hydroxide (KOH) Roth 6751 
Potassium sulfate (K2SO4) Roth CN79 
RPMI Medium 1640+Glutamax-I Gibco 72400 
Sodium acetate (CH3COONa) AppliChem A4555 
Sodium hydrogen carbonate (NaHCO3) AppliChem A1352 
Sodium chloride (NaCl) Roth P029 
Sodium dihydrogen phosphate monohydrate 
(NaH2PO4 ·H2O) 
AppliChem A7261 
di-sodium hydrogen phosphate (Na2HPO4) AppliChem/Roth A2943 / P030 
Sodium hydroxide (NaOH) Roth 6771 
Sodiumthiosulfat pentahydrate AppliChem A3822 
Sodium dodecylsulfate (SDS) Roth/AppliChem 2326 / A1112 
Silver nitrate (AgNO3) Roth 9370 
Sodium pyruvate 100 mM Gibco  11360 
Trichloroacetic acid (TCA) Merck 3744 
Tris(hydroxymethyl)-aminomethane (TRIS)  Roth 5429 
TRIS-hydrochloride (TRIS-HCl) AppliChem/Roth A1087 / 9090 
Trypsine-EDTA (0,05 %) Gibco  25300 
Tween 20 AppliChem A4974 
Yeast extract Roth  2363 
 




Dilute 20 % (w/v) d-glucose in dH2O, autoclave 
1 M potassium 
phosphate buffer, 
pH 6 
13.2 % (v/v) 1 M K2HPO4, 86.8 % (v/v) 1 M KH2PO4, pH set up 
with phosphoric acid or KOH, autoclave 
10x PBS 
   
1.37 M NaCl, 27 mM KCl, 80 mM Na2HPO4·2H2O, 18 mM 
KH2PO4 in dH2O, pH 7.4.  
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Name Composition 
For application: 1x 
50x TRIS-acetate-
EDTA-buffer (TAE) 
2 M TRIS; 5.71 % (v/v) acetic acid, 100 mM EDTA in dH2O, 
pH 8.5 
1.2 M TRIS-HCl-
buffer, pH 8.3 
1.2 M TRIS-HCl in dH2O, pH 8.3; autoclave 
High Salt LB 
Medium 




10 %FCS, 1 mM Sodium Pyruvate, 1x MEM NEAA, 2 mM L-
Glutamine, 100 units/ml Penicillin, 100µg/ml Streptomycin in 
RPMI1640+Glutamax I 
 
Table 11. PCR primers 
Name 
 
Sequence (5’ → 3’) TM (°C) 
TBEVc2x-ED3 s AAA GGT CTT ACG TAC ACA ATG TGT GAC 65.3 
TBEVc2x-ED3 as 
TAA TAA GCT TTT AAT GAT GAT GAT GAT 





AACCGAAGTCCCAGGCGTGC 64.4  
pMAL-Kolonie s  
 
ACG CGC AGA CTA ATT CGA GC 60.5 
pMAL-Kolonie as 
 







2.2.1. Molecular biological methods 
2.2.1.1. Reverse transcription of viral RNA 
Isolated positive stranded TBEV-RNA (obtained from Dr. Petra Fiebig) was reverse 
transcribed using AMV reverse transcriptase for 1 hour at 58°C. Therefore 5 µl RNA were 
denatured by incubation at 65°C for 1 minute, afterwards the reaction mix (Table 12) was 
added. 
Table 12. Reaction mix composition for reverse transcription 
Component  Volum e in µl  
5x Buffer 4 
dNTP 2.5 
Primer (RT-TBEV-E) 3 
RNAse inhibitor 0.5 
H2O 4 
AMV (10 U/µl) 1 
 
2.2.1.2. Polymerase Chain Reaction 
 The polymerase chain reaction (PCR) is a technique to amplify defined DNA regions 
by means of specific oligo-nucleotides (primers). Thermal cycling of repeated heating and 
cooling for DNA denaturation, annealing and extension leads in production of millions of 
copies of a particular DNA sequence. In this assignment the PCR reactions were composed 
as shown in Table 13. Amplification of gene sections coding for TBEV-ED3 was carried out 
with pfu –polymerase which exhibits a proof reading function using cDNA as template and 
Primers TBEVc2x-ED3 s and TBEVc2x-ED3 as. The following PCR programme was used: 
95°C 2’; 6x (95°C 20’’, 61°C 20’’, 72°C 30’’); 29x (95°C 20’’, 65°C 20’’, 72°C 30’’); 72°C 3’; 
4°C forever. It’s a two step PCR-programme with lower annealing temperature during first 6 
cycles as gene specific primer TBEVc2x-ED3 as contained a 5’ overhang and do not bind to 







Table 13.  Composition of PCR reaction mixtures 
Component 
Volume using  
pfu-polymerase  
(2.5U/µl) 
Platinum -Taq polymerase 
(5 U/µl) 
10x PCR buffer 5 µl 2 µl 
MgCl2 - 1.4 µl 
dNTP (10 mM each) 1 µl 0.5 µl 
primer forward (10 µm) 1 µl 0.5 µl 
primer reverse (10 µM) 1 µl 0.5 µl 
Polymerase 1 µl 0.2 µl 
Template 5 µl cDNA 10-50 ng DNA 
dH2O 36 µl Up to 20 µl 
Colony PCR is a method to control ligation and to verify the insert of the desired DNA 
fragments in transformants i.e. E. coli transformed with pMAl-c2x-TBEV-ED3.  
A portion of a colony was used as template DNA for the colony PCR and was applied 
directly to the PCR master mix. For colony PCR the primer pMAL-Kolonie s and 
pMAL-Kolonie as were used, as well as Platinum-Taq Polymerase. PCR programme was the 
following: 95°C 2’; 30x (95°C 30’’, 55°C 10’’, 72°C 30’’); 72°C 3’. 
2.2.1.3. DNA Sequencing 
For sequencing, the Big Dye Terminator Sequencing Kit was used, which is based on 
the chain-termination method by Frederick Sanger (Sanger et al., 1975). For automated 
sequencing each dideoxynucleotide is labelled with a different fluorochrome, so the chain 
terminated polynucleotides are distinguished as they pass by the detector (Brown, 2006). 
The reaction mixture was composed of 4 µl Big Dye Premix, 2 µl primer (10 µM), HPLC-H2O 
and 10-100 ng of the PCR-fragments or 200-500 ng plasmids DNA in a total volume of 10 µl. 
The sequencing reaction programme was: 96°C 2’; 25x (96°C 10’’, 55°C 15’’, 60°C 4’), at 
which the annealing temperature was adapted to the annealing temperature of the used 
primers. At the end of the reaction an ethanol-precipitation was carried out, with 70 µl 
HPLC-H2O, 10 µl 3 M sodium acetate pH 4.6-6.8 and 250 µl ethanol (100%) added to the 
sequencing mixture. After centrifugation for 35 minutes at 20800 x g at 22°C the pellet was 
washed with 250 µl ethanol (70%) and centrifuged at 20800 x g for 15 minutes. Afterwards 
pellet was dried in a vacuum centrifuge for 10 minutes at 35°C. Before analysis with the 
automatic sequencing apparatus ABI Prism 310, pellet was solved in 20 µl Hi-Di-formamide 
in the dark for at least 30 minutes. The data was then imported in Chromas Lite and 
analysed manually. 
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2.2.1.4. Agarose gel electrophoresis 
Agarose gel electrophoresis is a method to separate DNA fragments by length and 
was used to analyse products of PCR reactions or restriction digests. Addicted to the 
expected length of the fragments the concentration of agarose in the gel varies between 
0.8% (1.0-3.6kb) and 2% (0.2-0.6kb) in 1xTAE buffer. Finally ethidium bromide, a dye which 
fluoresces under UV light after incorporating into the DNA, was added to the gel-solution 
(4.5x10-4 mg/ml). The PCR or digestion samples were mixed with 6x loading dye (1 µl 
loading dye + 5 µl sample) and the electrophoresis was carried out in 1xTAE at an electric 
tension of 100 volt. Depending on the expected fragment length Gene Ruler 1kb DNA ladder 
or Gene Ruler 50bp DNA ladder (Fermentas) was used as marker. The gels were 
photographed with the MultiImage Light Cabinet of Alpha Innotech and the software 
ChemiImager 4400.  
2.2.1.5. DNA Purification 
High-quality and purified DNA, separated from enzymes, nucleotides, reaction 
buffers, primers and proteins, was important for further DNA applications such as cloning and 
sequencing. The Promega Wizard SV Gel and PCR Clean Up System or QIAquick® gel 
extraction kit was used to purify DNA fragments from amplification reactions or after 
restriction digestion according to instruction manual. The procedure is based on the ability of 
DNA to bind to silica in the presence of chaotropic salts. 
2.2.1.6. Determination of DNA concentration  
The concentration of the purified DNA was determined spectrophotometric with 
NanoDrop® spectrometer (PeqLab), which allowed the analysis of 2.0 µl samples. To 
estimate DNA concentration the absorbance of a DNA sample was measured at a 
wavelength of 260 nm against the elution buffer. DNA purity was estimated by determination 
of the A260/A280 ratio. An A260/A280 ratio between 1.7 and 2.0 represented a high-quality DNA 
sample. 
2.2.1.7. Restriction Digestion 
The restriction digestion procedure was required to cleave DNA molecules at specific 




Restriction digestion of PCR products and vector for ligation: 
Vector pMAL-C2X-ED3 was digested with XmnI and Hind III in a total volume of 30 µl 
in a recommended buffer system (buffer orange, Fermentas) with 1 µl of each enzyme, while 
PCR products were digested by Hind III only. After incubation period of 16 hours at 37°C 
enzymes were inactivated at 80°C for 20 minutes. Fragments were purified as described 
before (2.2.1.5). 
2.2.1.8. Ligation  
DNA ligation was used to join together insert DNA of ED3 with the plasmid 
pMAL-C2X, to generate the expression plasmid. It involved creating a phosphodiester bond 
between the 3’ hydroxyl bond of one nucleotide and the 5’ phosphate of another. The 
reaction was catalyzed by the enzyme T4 DNA ligase.  
The ligation mix contained digested vector and insert in a molar ratio of 1:6, 1 µl T4 
DNA-Ligase (5 U/µl), 1 µl of 10x T4 ligase buffer in a total volume of 10 µl. The solution was 
incubated at 20°C for 2 hours and the DNA ligase was denatured at 60°C afterwards. 
2.2.1.9. Transformation of E. coli 
During chemical transformation of the expression plasmid was introduced into 
competent E. coli BL21 (DE 3) cells. 5 µl of the ligation mix or 2 µl plasmid were added to 
50 µl of competent BL21 (DE 3) cells. After incubation on ice for 30 minutes, followed by heat 
shock at 42°C for 30 seconds and additional incubation on ice for 2 minutes, 300 µl SOC 
medium were added and the mixture was incubated at 37°C for 1 hour. 50-200 µl cell 
suspension was spread on a plate with LB agar containing 50 µg/ml of ampicillin, which 
served as a selective antibiotic. The plate incubated overnight at 37°C. In cells, which lack 
the ampicillin resistance gene, ampicillin caused cell death by intercalating into DNA and 
cleaving it. By colony PCR plasmids were checked for correct integration of PCR product. 
2.2.1.10. Purification of plasmids 
Transformed E. coli cells were grown in liquid LB media containing ampicillin for 
16 hours at 37°C and 220 rpm. Isolation of plasmid DNA from E. coli was performed using 
the QIAprep® Spin Miniprep Kit. The procedure is based on alkaline lysis of bacterial cells 
followed by adsorption of DNA onto silica in the presence of high salt. Isolation of plasmid 
DNA was done as recommended, except for DNA elution. Here nuclease free water was 
used instead of Tris buffer.  
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2.2.2. Biochemical methods 
2.2.2.1. Expression of TBEV-rED3 and WNV-rED3 prote in 
The expression plasmids pMal-c2x-TBEV-ED3 and WNV-D3pMAlTag2 were 
transformed into E. coli BL21 (DE 3); respectively. 
For expression a 5 ml overnight bacterial culture was inoculated into one litre of LB broth 
containing 2% glucose and ampicillin (100 µg/ml). The culture was grown in a shaker at 37°C 
and 200 rpm to an OD600 of approximately 0.6. By addition of IPTG with a final concentration 
of 0.3 mM protein expression was induced. After 3 hours shaking at 37°C 200 rpm, bacteria 
were harvested by centrifugation at 9,000 rpm for 15 minutes at 4°C, and pellet was  
re-suspended in 50 ml of column buffer for amylose affinity chromatography (20 mM 
Tris-HCI, 200 mM NaCl), and frozen at -20°C overnight.  
2.2.2.2. Purification of the fusion protein 
2.2.2.2.1.  Fusion protein purification by amylose affinity chromatography (MBP-tag)  
The MBP-fusion protein is purified from bacterial lysate by binding to an amylose 
resin and eluted off the amylose using maltose. Briefly, a 1 litre expression cell pellet was 
re-suspended in 50 mL washing buffer. The resulting solution was subjected to sonication 
(Branson 450 Sonifier) 3 times for 3 minutes with 2 minute intervals between sonications in 
order to avoid protein degradation due to heat produced by the sonicator’s sound waves. The 
solution was then centrifuged at 9,000 rpm for 15 minutes at 4°C. The supernatant was 
subsequently loaded on amylose resin filled columns. Unbound protein was removed by 
washing of affinity columns with 50 mL washing buffer. By addition of 25 ml elution buffer 
(20 mM Tris-HCL, 200 mM NaCl, 10 mM Maltose), target protein was eluted and fractions 
were collected for analysis by SDS-PAGE. Fractions containing the target protein were 
pooled and concentrated by dialysis against 20% PEG6000 in PBS for several hours 
(depending on the volume) using dialysis tubing with a 14 kDa molecular weight cutoff 
(MWCO) membrane. Subsequently, concentrated solution was dialyzed extensively against 





2.2.2.2.2.  Fusion protein purification by nickel a ffinity chromatography (6x-his-tag)  
  In order to improve protein purity, amylose purified-protein was subsequently 
subjected to nickel affinity chromatography (6x-his-tag) using Imidazole gradient among 
400 mM-1.2 M.  Nickel-NTA agarose beads (1 ml) were added to the column and 
equilibrated by addition of washing buffer (50 mM Tris-Cl, 300 mM NaCl, 20 mM imidazole). 
Subsequently, amylose purified protein was loaded onto the column. Unbound protein was 
removed by washing with washing buffer and target protein was eluted using a stepwise of 
increasing imidazole concentrations 0.4 M, 0.6 M, 0.8 M, 1 M and 1.2 M in buffer (50 mM 
Tris-Cl, 300 mM NaCl). Fractions were collected and analysed by SDS-PAGE. Fractions 
containing the target protein were combined and dialyzed against PBS over night at 4°C 
using a dialysis tube with a molecular weight cutoff of 1400 Da to remove imidazole and low 
molecular weight molecules. 
2.2.2.3. Sodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was used to separate proteins according to their molecular weight. In an 
electric field the proteins, negatively charged by treating with the denaturing agent SDS, 
migrated through the gel towards the anode. Depending on their size, each protein moved 
differently and covered another distance in the gel, with the largest proteins travelling the 
slowest. In this thesis a Tris-Tricin buffers were used (Schagger and von Jagow, 1987).   
Table 14. Composition of SDS-gels 
Reagent  10% running gel  4% stacking gel  
30% Acryl-/Bisacrylamide 4.9 ml 0.8 ml 
Tris/Cl/SDS (pH 8.45) 5.0 ml 1.55 ml 
dH2O 3.51 ml 3.89 ml 
Glycerol 1.58 ml - 
10% APS 0.05 ml 0.025 ml 
TEMED 0.01 ml 0.005 ml 
 
The electrophoresis apparatus was set up with cathode buffer covering the gels and 
the anode buffer outside of the gel cassette. 10 to 15 µl sample were mixed with 7 µl probe 
buffer each, were loaded on the gel after incubation at 95°C for five minutes together with 
1 µl prestained protein ladder. The common running conditions were 150 volt for 70 minutes. 
The gels could then be used for further analysis by western blot (protein extracts) or silver 
staining. 
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2.2.2.4. Silver staining 
To detect proteins after electrophoresis separation on polyacrylamide gels silver 
staining was carried out according to the protocol of Nesterenko et al., 1994 shown in 
Table 15. The procedure is based on binding of silver ions to certain amino acid residues (i.e. 
aspartate, glutamate, histidine, cysteine and lysine) and subsequent reduction of silver ions 
to metallic silver by formaldehyde. All these steps were carried out at permanent agitation 
and room temperature. After staining, the gels were documented with Multi-Image Light 
Cabinet (Alpha Innotech).  
Table 15. Protocol for silver staining 
Steps Solutions Time 
Fixation 60ml acetone (50%), 1.5ml TCA (50%), 25µl formaldehyde (37%)  5 min 
Washing dH2O  3 x 5s 
Pre-treatment 60ml acetone (50%) 5 min 
Pre-treatment 0.1ml sodiumthiosulfate-pentahydrate (10%) in 60ml  dH2O 1 min 
Washing dH2O 3 x 5s 
Impregnating 0.8ml silver nitrate, 0.6ml formaldehyde in 60ml dH2O 8min  
Washing dH2O 2 x 5s 
Developing 
solution 
1.2g sodium carbonate, 25µl formaldehyde, 25µl 
sodiumthiosulfate-pentahydrate in 60ml dH2O 
10-30s 
Stop solution 60ml acetic acid (1%) 30s 
Washing dH2O 10s 
 
2.2.2.5. Western Blot 
After electrophoresis, the separated molecules are transferred or blotted onto 
polyvinylidene difluoride (PVDF) membrane. The PVDF membranes containing transferred 
proteins were blocked for 30 minutes with 5% skimmed milk solubilized in PBS buffer, and 
incubated overnight at 4°C with primary antibodies diluted in 5% skimmed milk in PBS. 
Immunoreactive bands were detected with an appropriate secondary antibody conjugated to 
HRP diluted in PBS for 90 minutes. After each step, the membranes were washed three 
times with PBS and were developed with enhanced chemiluninescence ECL substrate 
(Luminol Enhancer and Peroxide solutions). Labeled proteins were visualized using the 
chemiluminescence imaging system Intelligent Dark Box II and LAS-1000 camera.   
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2.2.2.6. Bradford Protein Assay 
 The evaluation of the protein concentration was carried out using the method of 
Bradford, 1976. This method is based on the complexion of Coomassie-Brilliant-Blue G250 
with proteins. The red-brown form of the dye is converted into its blue form. This absorbance 
shift can be measured spectroscopic at 595 nm.  
To obtain a standard curve dilution series of bovine y-globulin (2 mg/ml) from 
0-1000 µg/ml were made in Millipore H2O and assayed in triplicate. Sample which protein 
concentration had to be determined was diluted in Millipore H2O, too. Bradford concentrate 
was diluted 1:4 in H2O. 240 µl Bradford-reagent were pipetted into a well of a 96 well-plate 
and 10 µl samples were added and mixed. 10 µl Millipore H2O in 240 µl Bradford reagent 
served as blank values. After incubation of 30 minutes at room temperature in the dark, the 
colour change could be measured with Tecan Sunrise ELISA reader.  
2.2.2.7. Indirect ELISA 
The analysis of sera from infected people for TBEV and WNV antibodies was carried 
out by ELISA. High binding microtiter plates (Greiner Bio-one) were coated with 500 ng/well 
recombinant protein in 0.1 M sodium carbonate buffer (pH 9.6) at 40C overnight. The plates 
were washed with PBS (pH 7.4) containing 0.05% (v/v) Tween 20 (PBS-T). Remaining sites 
were blocked with 5% skimmed milk in PBS/0.05% Tween 20 for 1 hour at 370C. Plates were 
then incubated with the test sera diluted in blocking buffer for 2 hours at 370C at a 1:200 
dilution (50 µl/well). The secondary antibody was a peroxidase-conjugated rabbit anti-human 
IgG diluted in blocking solution (1:4000) and incubated for 90 minutes at 370C. The 
3,3′,5,5′-Tetramethylbenzidine (TMB) peroxidase substrate system was used to visualize 
TBEV and WNV-specific antibody (100 µl/well). Then, the reaction was stopped with 50 µL of 
1N H2SO4. The samples were measured at 450/650nm wavelength with Tecan Sunrise 
ELISA reader. Between each step, plates were washed five times using washing buffer. 
Wells filled with blocking buffer instead of serum sample functioned as blank, which was 
subtracted from each OD-value. Predefined sera tested negative for flaviviruses were used 
as negative controls to determine the cut off value as follows: cut off = geometric 




2.2.3. Cell culture and Virological Methods 
2.2.3.1. Cell culture of adherent growing cells  
Cell culture is the process in which cells grow under defined conditions. In this 
assignment Vero cells were used for propagation of WNV and PS cells for TBEV 
neutralisation test. Cells were cultivated in tissue culture flask with DMEM supplemented with 
5% FCS for Vero cells or 10 % FCS for PS cells at 37°C, 5% CO2 and 90% humidity. Two 
times per week cells were splitted.  Medium was removed, cells were washed with PBS and 
trypsine was added to loose the cells from the ground. After incubation for 2-5 minutes 
reaction was stopped by addition of DMEM containing FCS, cells were resuspended by 
pipetting up and down and splitted 1:10.  
2.2.3.2. Cell count 
For determination of the cell count of living cells, staining of dead cells with trypan 
blue was carried out. 20 µl cell suspension was mixed with 20 µl trypan blue solution (0.4%). 
10 µl of this mixture was placed into a NEUBAUER-microscope counting chamber. The 
unstained living cells were counted in two large squares. The living cell count could be 
calculated in cells/ml with the arithmetic average of these squares (Formula 1).  











A area of one large square (1 mm²) 
T chamber depth (0.1 mm) 








2.2.3.3. Tissue Culture Infection Dose 50 (TCID 50) 
The tissue culture infection dose (TCID50) assay, an endpoint dilution assay, was 
used to quantify the amount of virus required to produce a cytopathic effect in 50% of 
inoculated tissue culture cells.  
The procedure was adapted to the micro-neutralisation test (2.2.3.4.) and was carried 
out in a 96 well plate. PS cells were used for TBEV and Vero cells for WNV quantification. 
Therefore, 50 µl of DMEM were added to each well and virus was diluted serial from 10-1 to 
10-10 in DMEM without supplements to be assayed fourfold. 50 µl of virus dilution were added 
to each well.  As negative control DMEM without FCS was added to the wells. After 1 hour 
incubation at 37°C, 100 µl with 1x104 cells in DMEM supplemented with 5 % FCS were 
added per well. Plates were further incubated at 37°C and 5% CO2 and 90% humidity for five 
days and stained for colorimetric results with neutral red as described by Taketa-Graham et 
al., 2010. Therefore the supernatant was removed and 100 µl neutral red dye (prepared as a 
1:25 dilution of a 0.33% stock in dH2O) was added and plates were incubated for 75 minutes 
at 37°C and 5% CO2. Afterwards the dye was removed and cells washed twice with 100 µl 
PBS per well. After a final aspiration cycle 100 µl of acid alcohol (50% ethanol and 1% acetic 
acid in dH2O) was added to all wells. After 30 minutes of incubation in which the neutral red 
retained by remaining living cells is solubilised plates were read on Tecan Sunrise ELISA 
reader at wavelengths of 540/0nm. For quantification the geometric mean of the OD values 
obtained for cell control (CC) was calculated and of the lowest virus dilution (V) used. The 
endpoint OD value (cut off) was calculated using the following formula: cut off 
value = 0.5*(CC-V) + V. 
Wells with OD values above the cut off are regarded as negative (living cells), wells 
with OD values below the cut off are positive, i.e. virus infection and CPE. TCID50 was 
calculated according to the formula (Formula 2) of Spearman and Kaerber (Kaerber, 1931). 
Working steps, containing virus, were carried out in a bio-safety level 3 laboratory.   














X0 Logarithm of the reciprocal value of the lowest dilution, 
at which all test units are positive (disrupted cell layer) 
d Logarithm of dilution interval 
(10x-dilution: d = 1) 
n Number of test units per dilution 
r Amount of positive test units per dilution level from 
and including X0 
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2.2.3.4. Micro-neutralisation test 
The micro-neutralisation test for determination of highest serum dilution resulting in 
50% protection of inoculated tissue culture with a determined amount of virus was performed 
according to the determination of TCID50.  
Serum was diluted in a two fold serial dilution in DMEM, starting at 1:25. 50 µl of 
serum dilution was added to each well to be assayed four fold. 50 µl virus dilution with a 
concentration of 100 TCID50 were added to 3 of the 4 serum dilution containing wells. To the 
fourth 50 µl DMEM without supplements was added as control. After incubation of this 
mixture for 1 hour at 37°C 100 µl with 1x104 cells in DMEM supplemented with 5% FCS were 
added per well. Plates were further incubated at 37°C and 5% CO2 and 90% humidity for five 
days and stained for colorimetric results with neutral red as described above (2.2.3.3). In 
each test, used virus stock was titrated again by diluting 10-1 to 10-8 and the used virus 
dilution was also back titrated using it undiluted to 10-6. Those performing too low or too high 
virus doses were not accepted and neutralisation test was repeated.  
  Neutralizing antibody titres were expressed as neutralizing dose that protects 50% of 
the cell cultures (ND50) calculated according to Behrens & Kaerber (Taketa-Graham et 
al., 2010). 
Formula 3. Calculation of ND50  
 
ND50= V[d*(S-0,5)] 
V Logarithm of the reciprocal value of the serum dilution, 
at which all test units are positive (disrupted cell layer) 
d Logarithm of dilution interval 
(10x-dilution: d = 1) 
S amount of all positive test units from 0% to 100% 
divided by the number of test units per dilution  
 
ND50 ≥10 were considered protective antibodies. Evidence of neutralizing antibodies 
was used as a surrogate parameter for this purpose since their formation is of decisive 
importance for virus elimination in TBE infection and results in protection against disease 





2.2.3.5. Purification of virus 
 Vero cells were grown and infected with TBEV and WNV at a multiplicity of infection 
(MOI) of approximately 0.01. The infected cell culture supernatant was harvested on day 
7 post infection. Cell debris was removed by centrifugation at 4,000 rpm for 30 minutes at 
4ºC. The supernatant was layered on top of a 5 ml sucrose cushion (25 % sucrose in PBS). 
The virus was pelleted by ultracentrifugation at 100 000 x g for 4 hours at 4ºC to remove low 
molecular weight contaminants such as soluble proteins. The supernatant was poured off 
and the tubes were briefly left upside down on chromatography paper in order to remove 
excess liquid from the side of the tubes and virus pellet was resuspended in 1 ml PBS.   
2.2.3.6. Virus inactivation by H 2O2  
Inactivation was performed by addition of H2O2 as described by Amanna et al., 2002. 
Briefly, H2O2 with a final concentration of 3% was added to the concentrated virus and was 
incubated at room temperature for 2 hours with vortexing every 30 minutes. Adjacent sample 
was dialysed extensively against PBS to remove H2O2. Inactivation was verified by infection 
of cell culture before virus was used as antigen in ELISPOT or ELISA. Concentration was 
determined using Bradford assay.  
2.2.4.  ELISPOT Assay 
To quantify antibody secreting B-cells, a B-cell ELISPOT assay (Enzyme-linked 
immunospot assay) is performed. This method based on the detection of antibody secreted 
by B cells and was published in 1983 by Czerkinsky et al. ELISPOT was performed using 
ELISpotPLUS for Human IgG Kit from MABTECH according to the manufacturer’s instructions. 
Performance  
Isolation of peripheral blood mononuclear cells (PB MCs) 
15 ml heparinized venous blood was diluted with an equal volume of PBS and was 
carefully layered on to 15 ml Histopaque (Sigma). After centrifugation at 1000 x g for 
20 minutes at 20°C, PBMCs were remained at the interface of plasma and Histopaque. Red 
blood cells (RBCs) and other cell debris were precipitated at the bottom of the tube. The 
mononuclear cells were then collected carefully with a Pasteur pipette and were washed 
twice in PBS at 400 x g for 15 minutes at 20°C. 
Finally, the PBMCs were resuspended in 5 ml of supplemented RPMI medium 
(Table 10) and counted. Therefore, 10 µl of cell suspension was added to 50 µl PBS and 40 
µl trypanblue. 
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Activation of memory B-cells 
For activation 1x106 cells were plated per well of a 24 well plate in supplemented 
RPMI which contained 1 µg/ml R484 and 10 ng/ml rhIL-2. Cells were incubated for 3 days at 
37°C, 5% CO2 in a humidified incubator. About 1x10
6 cells were placed in a well of a 96 well 
plate without stimulation agent and incubated likewise. 
Preparation of ELISPOT plates    
To test for antigen specific memory B-cells sterile 96-well Multiscreen-IP filter plates 
with PVDF membranes (Millipore) provided in the kit were pretreated with 50 µl 70% ethanol 
for 45 seconds and then washed five times with sterile water before coating. Coating 
antigens including TBEV-rED3, WNV-rED3, inactivated TBEV, Influenza virus nucleoprotein 
(NP) and MBP were diluted to 1 µg/well in sterile phosphate buffered saline (PBS) and 
anti-IgG coating mAbs were diluted to 10 µg/ml in PBS and added to the plate. The plates 
were then incubated overnight at 4°C. 
Incubation of cells in ELISPOT plate 
On day of ELISPOT performance plates were washed and blocked with 
supplemented RPMI for 30 minutes at 37°C. After the 72 hour pre-activation, activated 
PBMCs were harvested and washed three times with RPMI 1640 before counting. The cells 
were resuspended and added to the plates with 100 µl cell suspension/well with 
concentration of 1x105 and 3x105 cells/well in antigen coated wells while 500 and 1000 
cells/well were placed in anti-IgG coated wells (Table 16). Each cell concentration was tested 
in duplicate. Plates were incubated absolutely vibration-free for 20-24 hours at 37°C, 5% CO2 









Table 16. Antigens and cell concentrations for ELISPOT coating 
Antigen Function 
Plated number of 
activated cells 
Plated number 
of non activated 
cells 
TBEV-rED3 
To be tested specific 
antigen 
100 000 300 000 - 
WNV-rED3 
To be tested specific 
antigen 
100 000 300 000 - 
inactivated TBE 
whole virus 
To be tested specific 
antigen 
100 000 300 000 - 
MBP 
Control antigen for 
unspecific reactions 
with MBP moiety of 
fusion proteins 
100 000 300 000 - 
Influenza virus 
Nucleoprotein 
Positive control for 
ELISPOT 
100 000 300 000 - 
Anti-IgG-
immunoglobuline 
Activation control 500 1000 1000 
 
Detection of Spots 
After 20 hours of incubation, the cells were discarded and the plates were washed 
with PBS (5×200 µl/well). Biotinylated anti-IgG detection mAbs diluted to a concentration of 
1 µg/ml in PBS/0.5% FCS were added to the plate wells and incubated for 2 hours at 37°C. 
The plates were washed with PBS (5×200 µl/well) before Streptavidin conjugated with 
Alkaline-Phosphatase (SA–ALP) (Mabtech) diluted 1/1000 in PBS/ 0.5% FCS was added 
and incubated for 1 hour at 37°C. Unbound conjugate was washed away with PBS 
(5×200 µl/well). BCIP/NBT-plus substrate (Mabtech) was filtered through a 0.45 µm-filter and 
100 µl/well was added to the wells and incubated for 15 minutes at room temperature. The 
reaction was stopped by rinsing the plates with tap water. The plates were then left to dry 
overnight in darkness. 
Plates were counted on an ELISPOT reader (AID ELISpot 04 plate reader, 
Autoimmun Diagnostika GmbH). Spots in wells with control protein (MBP) were subtracted 
from the number of spots in wells coated with specific antigen (TBEV-rED3, WNV-rED3 and 
NP).  
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Calculation of the memory B-cell frequencies 
 
  The frequency of antigen-specific cells was calculated as the percentage of total 
antibody-secreting cells according to the Formula 4 (Bussmann et al., 2010). 




2.3.  Study design: study subjects and statistical analysis 
Nineteen normal adult healthy volunteers were enrolled in the analysis (7 males; 12 
females). Twelve of 19 individuals had get a basis and booster immunization against TBE, in 
which, six of those individuals vaccinated less than 5 years ago received multiple 
vaccinations and six individuals vaccinated more than 10 years ago at time of blood draw. 
The year of the most recent vaccination was used to establish the year’s post-vaccination of 
the vaccine in all data analysis. Seven TBE unvaccinated individuals were also determined 
for TBE specific memory B cells as negative control; four of those individuals were naturally 
infected with Dengue virus. 
Since the data were not distributed normally, a Mann–Whitney test was performed to 
compare values between groups. Pearsons’s correlation as well as linear regression was 
done to analyse the correlation between variables.  
Geometric mean titers (GMT) were calculated with 95% confidence intervals (CI). 
Confidence intervals of GMTs were calculated based on the assumption of a log-normal 
distribution of titres. 
Analyses were performed with SPSS (SPSS Inc. Version 18) and GraphPad Prism 
(GraphPad Software, Inc. Version 5.0). For all statistical analyses, p values less than 0.05 
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CHAPTER 3. RESULTS 
 
3.1.  Expression and purification of recombinant envelop e domain 3 protein (rED3) 
and evaluation of its use for TBE diagnosis by rED3 -based ELISA 
3.1.1. Construction of the pMAL-ED3 expression vect or  
In order to express the TBEV rED3 in E. coli (Figure 5) the vector pMAl-c2x was used 
which contains the malE gene that encodes the maltose-binding protein (MBP) under the 
control of the promoter Ptac. Additionally, Ptac bears an operator region negatively regulated 
by the lacI repressor. Therefore, the induction of gene expression from such operon could be 
controlled by IPTG. The ED3 coding sequence was cloned downstream from malE gene 
using the XmnI and HindIII site to ensure a directed insertion of the fragment and produce 















Figure 5. The diagram illustrates the strategy employed to construct the pMAL-ED3 vector. The cDNA 
fragment was cloned into the polylinker of the expression vector pMAL-c2X, as described in Materials 
and Methods. Features of the pMAL-c2X expression vector, such as the factor Xa cleavage site, the 
malE, lacIq, lacZα and Ampr genes, the polylinker region, the replication origins of M13 phage, the Ptac 







The first step to clone pMAL-TBEV-ED3 was the amplification of the coding region of 
domain 3 of TBEV structural gene E by PCR using gene specific primers TBEVc2x-ED3 s 
and TBEVc2x-ED3 as. cDNA derived by reverse transcription of viral RNA was used as 
template. Primer TBEVc2x-ED3 as includes a 5' extension with a HindIII site to facilitate 
directed integration into restricted pMAL-c2x. Additionally, it contained the coding sequence 
for a histidine tag for easier purification of the recombinant protein. Corresponding to the 
length of ED3 the PCR reaction produced a 319 base pair (bp)-long fragment as verified by 




[bp]                 M          1           2
319bp
 
Figure 6. PCR products showed a successful amplification of gene coding for TBEV-ED3. A 
corresponding band of 319 bp was revealed (lane 1 and 2), M: molecular weight marker (GeneRuler 
Low range DNA ladder). 
 
For the construction of pMAL-TBEV-ED3 the PCR products were purified and 
digested with Xmnl and HindIII, as was pMAL-c2x vector. Amplicons were ligated into the 
vector using T4-DNA-Ligase.   
The cloned expression plasmids were transformed into E. coli BL21 (DE3) cells. 
Positive selected clones were confirmed by colony PCR using pMAL-kolonie s and 
pMAL-kolonie as primers. As shown in Figure 7, using DNA from clone 1(cl1), clone 2 (cl2), 
clone 3 (cl3) and clone 4 (cl4) as template fragments of 436 bp were obtained as visualized 
by electrophoresis. In the control reaction with pMAL-c2x vector as template the fragments 
are smaller, 165 bp. Thus the clones 1, 2, 3 and 4 contain the ED3 gene.  
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Figure 7.  Transformed E.coli containing the pMAL-ED3 vector was confirmed by colony PCR in 
comparison to empty vector pMA-c2x. PCR with DNA of recombinant clones cl1, cl2, cl3, cl4 resulted 
in a 436 bp sized fragment. M: molecular weight marker (GeneRuler Low range DNA ladder). 
 
Overnight cultured E. coli transformants were then used in subsequent 
screening experiments. The plasmids were isolated from the bacterial cells and 
digested with restriction enzymes HindIII and BglII. Gel electrophoresis analysis shows 
that a double restriction produced the expected fragments of 5837 and 1080 bp; 
respectively (Figure 8). 






Figure 8.  pMAL-ED3 was characterized by enzymatic restriction. Lane: 1, 2, BglII and HindIII 
digestion. The expected size of digested fragments is indicated on the left. M: molecular weight 
marker (GeneRuler 1kb DNA ladder). 
 
 
The next screening step for recombinants was DNA sequencing using primer 
pMAL-klonie s to confirm a correct sequence and insertion of ED3 coding DNA fragment.  
For expression, one clone was chosen, which inserted fragment showed 100% 
concordance with the corresponding region of ED3 cDNA, i.e. clone 2.  
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3.1.2. Expression and purification of TBEV-rED3 and  WNV-rED3 protein in E. coli 
According to the used cloning strategy the vector pMAL-c2x-TBEV-ED3 encodes a 
MBP-fusion protein of 489 amino acids (aa). The N-terminal 387 aa encode for MBP with 
amino acids of the polylinker, whereas 102 residues correspond to TBEV-ED3 with a 
C-terminal (His)6-tag. The vector pMAL-WNV-ED3, which was obtained from Dr. Ulbert 
(Fraunhofer Institute, Leipzig), was cloned by BamHI and XhoI. Thus, it encodes a protein of 
504 amino acids with 393 residues comprising the N-terminal MBP with polylinker and 111 
residues comprising the WNV-ED3 with C-terminal (His)6-tag. Theoretical molecular weights 
are shown in Table 17. 
Table 17.  Theoretical molecular weight of recombinant proteins 
 
Protein TBEV-rED3 WNV-rED3 
Molecular weight of MBP-fusion protein [kDa] 53.9 55.0 
Molecular weight of rED3 [kDa] 10.61 10.81 
 
Cytoplasmic expression of both proteins was successful, as shown in Figure 9 
representative for the expression of TBEV-rED3. Three hours after induction of protein 
expression with IPTG, dominant bands were detected in lane AI at 54 kDa, which are not 










[kDa]     M         BI         AI
54kDa
 
Figure 9. Analysis of MBP-ED3 fusion protein expression after addition of final 0.3 mM IPTG. Cell 
lysates were obtained before (BI) and after 3 hours of IPTG induction (AI). Proteins were fractioned by 





To determine whether these bands corresponding to the fusion protein, a Western 
blot analysis of IPTG induced cultures was performed. As shown representative in Figure 10 
for MBP-TBEV-ED3 by using his tag specific antibody, a band with apparent molecular mass 
of 54 kDa was revealed. Overall, the immunoblot analysis corroborated that the protein with 
apparent molecular weight of 54 kDa, induced after IPTG treatment corresponds to the 
fusion MBP-ED3 protein. The smaller bands detected by the antibody probably represent 












Figure 10.   Analysis of protein expression before (BI) and after (AI) IPTG induction by Western blot 
using histag specific antibody. 
 
The protein purification process was started using amylose affinity chromatography. 
Purification results are shown representative for protein MBP-TBEV-rED3 in Figure 11. 
A single prominent band migrating at the 54 kDa marker visible in the silver-stained gel was 
detected in the elution fractions 1-4 (Figure 11A) indicating the successful purification of the 
MBP-ED3 fusion protein. Anyway, a band of the same size is visible in the flow through (F), 
which indicates insufficient binding of the protein to the amylose. Eluted fractions containing 
the fusion protein were pooled and purified further by nickel affinity chromatography using an 
imidazole gradient. Again the flow through contains the target protein (Figure 11B). Bound 























[kDa]     M      F        W       E1       E2      E3       E4      E5      E6
B  
Figure 11.  Purification of fusion protein 3 hours after induction with IPTG The protein was purified by 
amylose resin column (A) followed by nickel affinity chromatography (B). Purification was analysed by 
10% SDS-PAGE and stained with silver.  
BI: before IPTG induction; AI: after IPTG induction; F: flow through; W: wash fraction.  
E1-E4: eluted fractions of amylose resin column by 10 mM amylose (A)  
E1-E6: eluted fractions of nickel column purification by increased imidazole concentration (400 mM, 
600 mM, 800 mM, 1 M, 1.2 M, 1.4 M imidazole; respectively (B) 
 
Finally, fractions containing the target protein were pooled and dialyzed in PBS 
(pH 7.4) overnight in order to remove the high imidazole concentration and small weight 
molecules.  
3.1.3. Analysis of proteins as antigens by Western Blot 
In order to analyse antigen specificity of TBEV-rED3 and WNV-rED3 predefined sera 
were analysed on blotted purified rED3 proteins (1µg per lane). By the TBEV and WNV 
positive serum, rED3s were detected as proteins with an apparent molecular weight of 
approximately 55 kDa. However, application of WNV positive sera or TBEV positive sera on 
WNV- or TBEV-rED3 protein resulted in a reaction with both proteins and similar results were 
obtained when negative serum was applied (Figure 12A, 12B and 12C). Moreover, the 
reactivity between antibodies and MBP in all positive and negative sera was observed. Thus, 
in Western Blot a discrimination of WNV positive sera and TBEV positive sera using rED3 
proteins is not possible, probably due to either linearization of the protein and reaction of 
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A B C  
Figure 12.  Immunoassay based on recombinant ED3 protein, immobilized on PVDF membrane. 
Following sera were used (A) TBEV positive serum; (B) WNV positive serum; (C) Negative serum. All 
sera were diluted 1:20. 1: TBEV-rED3; 2: WNV-rED3; 3: MBP. 
 
3.1.4. Analysis of proteins as antigens by Enzyme-l inked immunosorbent assay 
(ELISA) 
The first step was to determine the specificity of sera for the immobilized antigen. 
Therefore, soluble rED3 protein at concentrations from 100 ng to 1.0 µg per well was coated 
in ELISA plate. TBE positive and negative sera were tested to identify optimal antigen 
concentration. This result proved that binding of TBE virus-specific serum antibodies with the 
best signal-to-noise ratio was obtained at 500 ng/well (10 µg/ml). An increased concentration 
of antigen did not result in higher OD values (Figure 13A). Thus, 500 ng/well of rED3 was 
selected for overall ELISA coating. 
Next, in order to determine minimum background and maximum sensitivity, TBE 
virus-positive and negative anti-sera were serially diluted from 1:50 to 1:1600 in 5% non-fat 
milk. The results showed that at a dilution of 1:50, the background of the negative sera was 
relatively high. At a dilution of 1:200 the positive sera produced an absorbance reading that 
was 6-fold higher than the negative serum reading. Additionally, OD450nm value at this dilution 
showed a minimum background reading of 0.153 (Figure 13B). Thus, the sera were used in 
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Figure 13.  Titration curves for antigen concentration (A) and serum (B) for minimum background and 
maximum sensitivity in ELISA. All sera were tested in duplicate against TBEV-rED3 protein (values are 
the mean OD450nm with standard deviation (SD)). Optimum values with the best signal-to-noise ratio 
were obtained at antigen concentration of 500 ng/well and at a serum dilution of 1:200. Error bars 
present as standard deviation. 
 
To evaluate whether the rED3 based ELISA was applicable for serological diagnosis, 
28 serum samples from TBE post-infected and vaccinated individuals were tested. The 
results were compared with those obtained using commercial ELISA kit (Figure 14 and Table 
18). Of the 28 serum samples examined, 23 were positive, 5 were negative on commercial 
IgG ELISA. The 23 serum samples shown to be positive by commercial IgG ELISA, were 
also positive by IgG-ELISA using rED3. Five serum samples that were negative by 


















Figure 14. Comparison of rED3-based ELISA and commercial ELISA kit in TBE diagnosis (column 
values shown as OD450nm value of sample – cut off value). Error bars present as standard deviation.
  




IgG ELISA using recombinant antigen (rED3) 
Positive Negative Total 
Positive 23 0 23 
Negative 5 5 5 
Total 28 5 28 
 
It has been reported that antibodies against flaviviruses show cross-reactivity with 
other flavivirus antigens (Dobler et al., 1996, Holzmann et al., 1996; Litzba et al., 
2013; Niedrig et al., 2001). Therefore, 14 serum samples from WNV and 4 DENV infected 
donors were tested using commercial and rED3-based ELISA. All 18 of these serum samples 
were negative by the rED3 ELISA, while up to 11 WNV (80%) and all 4 DENV samples 
showed cross-reactivity with commercial IgG ELISA (Figure 15). Cut-off values for 



















Figure 15.  Analysis for cross-reactivity with other flaviviruses by rED3-based ELISA and commercial 
IgG ELISA using WNV positive human sera and DENV positive sera (column values shown as 
OD450nm value of sample – cut off value). Error bars present as standard deviation. 
 
In conclusion, the TBEV-rED3 demonstrated significant potential for the development 
of rED3-based ELISA diagnostic assay for detection of specific IgG to TBEV in serum 
specimens and for differentiation of infections caused by TBE serogroup and mosquito-borne 
flaviviruses. 
3.2. Determination of antigen-specific memory B cel ls in TBE vaccinated individuals 
by Enzyme-linked immunospot (ELISPOT) 
To better characterize human B cell responses after vaccination, an ELISPOT-based 
assay to quantitate Ag-specific memory B cells in human blood was applied. In ELISPOT, 
TBEV-rED3, inactivated whole TBEV, Influenza virus nucleoprotein (NP) and WNV-rED3 
were used as antigens to evaluate specificity for identification of memory B cells against 
TBEV. To be able to measure antibody secreting cells (ASCs), the B-cells within the isolated 
PBMCs were activated by incubation with a combination of R848 (Resiquimod) and rhIL-2 for 
3 days. A representative culture is shown in Figure 16. Stimulation of PBMCs with 
R848 and rhIL-2 for 3 days resulted in a marginal proliferation of cells visible as proliferation 
clusters. 
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A B  
Figure 16.  Bright field microscopy of non-stimulated PBMCs (A) and R848 and rhIL-2 stimulated 
PBMCs after 3 days of incubation (B), arrows indicated proliferating memory B cells. 
 
Figure 17 shows the ELISPOT results of TBE vaccinated and non-vaccinated blood 
donor. In each ELISPOT-assay 1000 cells were plated on anti-IgG coated wells to control 
activation of B-cells. So in both samples spots were detected. On anti-IgG wells 105 
non-activated cells were plated to screen for ASCs within the PBMC preparation. If spots 
would have been detected they were subtracted from spots on IgG. MBP coated wells 
functioned as control as specific antigens were MBP-fusion proteins. In this example no 
spots were detected on MBP in both samples. If so, spots were subtracted from antigen 
specific spots. For Influenza NP, which was used as another control, spots were detected in 
both samples but TBEV-rED3 specific memory B cells were detected in the blood of TBE 
vaccine recipient only. Moreover, Ag specific ASCs were only detected in TBEV-rED3 coated 
wells, not on inactivated whole TBEV or in WNV-rED3 coated wells (Figure 17). This 
demonstrated that TBEV-rED3 was superior to inactivated whole TBEV for determination of 


















Figure 17.  A representative ELISPOT of a vaccinated and a non-vaccinated donor 
 
3.2.1. Analysis of vaccine status by ELISPOT 
To analyse applicability of ELISPOT for evaluation of vaccine status 19 blood 
samples were investigated. From these 12 donors were vaccinated against TBEV at different 
time points in the past. TBEV-rED3 specific memory B cells presenting as ASCs were 
detected in eleven of 12 TBE vaccinated individuals ranging from 5 to 50 ASCs per 106 
PBMCs (median=10 with a 25% percentile of 5, a 75% percentile of 20.25). In seven 
unvaccinated individuals no TBE-specific memory B cells were detected. Additionally, no 
cross-reactivity in persons infected with Dengue virus was detected by this assay 
(Appendix 1). There was a significant difference in TBE-rED3 specific ASCs (p=0.0012) 





Figure 18.  Specific memory B cells in group of vaccinated individuals compared to non-vaccinated 
group. There was significant difference between TBE vaccinated and non-vaccinated group 
(p=0.0012) 
 
A frequency of antigen-specific ASCs was calculated as the numbers of antigen 
specific IgG ASCs per total IgG ASCs (Appendix 1). The result showed that frequency of 
TBVE-rED3 specific IgG ASCs ranged from 0.016% to 0.188% (median=0.050 with a 25% 
percentile of 0.025, a 75% percentile of 0.072) per total IgG producing cells. Thus, it is lower 
than frequency of NP specific IgG ASCs between 0.012% and 0.510% (median=0.104 with a 
25% percentile of 0.060, a 75% percentile of 0.180) (Figure 19). 
 
 
Figure 19.  The frequency of antigen specific ASCs were detected in TBE and Influenza vaccinated 





The TBE vaccinated individual number 4 who got a TBE booster 4 years ago 
obtained the highest frequency of antigen specific memory B cells (0.188%). Other vaccinees 
who obtained the last booster 11 years and 23 years ago (donor #7 and #12) exhibited lower 
antigen specific ASC frequencies of 0.06% and 0.1%; respectively. Lower ASC frequency 
was also observed in vaccinee who obtained one booster 1 year ago (donor #1). Donor #8 
was found TBEV-rED3 specific IgG ASCs with only single dose of primary vaccination past 
11 years. Donor #9, who received two doses of primary vaccination 17 years ago, was both 
negative with anti-TBE antibodies in plasma and undetectable any TBEV-rED3 specific IgG 





















































































Figure 20. Frequency of antigen specific ASCs regarded time since vaccination by years and number 
of primary and booster doses in TBE vaccinated individuals 
 
Antigen-specific IgG ASCs were analysed in groups with primary and booster 
vaccination. As shown in Figure 21 frequency of TBEV-rED3 specific ASCs was slightly 
higher in a booster group (median=0.081 with a 25% percentile of 0.053, a 75% percentile of 
0.165) compared to primary vaccination group (median=0.037 with a 25% percentile of 
0.018, a 75% percentile of 0.062). A significant difference between two groups was found 
(p<0.05). Therefore, the accumulation of antigen specific ASCs depended on the booster 































Figure 21. Frequency of antigen specific ASCs between groups with primary doses and booster. 
Median values are represented by lines. 
 
Conclusion: longevity differs, depends on immune response of the individual. 
Nevertheless, the donors were grouped into a group of individuals vaccinated 1-5 years ago 
(mean of 2.5 years) and a group of individuals vaccinated more than 10 years ago (mean of 
16.5 years). The frequency of TBEV-rED3 specific IgG ASCs in immunized group with 1-5 
years of post-vaccination (median=0.058 with a 25% percentile of 0.022, a 75% percentile of 
0.103) was only slightly increased than that in group with longer time of post vaccination 
(median=0.048 with a 25% percentile of 0.021, a 75% percentile of 0.073). However, 
statistical analysis showed no significant difference (p >0.05) in the frequency between the 
two compared groups (Figure 22). 































Figure 22.  Comparison of longevity of TBE vaccine-specific B cell memory in individuals vaccinated 
1-5 years (mean 2.5 yrs) and >10 years (mean 16.5 yrs). Individuals were tested for TBE-specific 
memory B cells using rED3 as the ELISPOT coating Ag and mean of frequency of TBEV-rED3 specific 






3.2.2. Determination of plasma antibody and neutral izing antibody titres 
Additionally, plasma of all donors was analysed by commercial and rED3-based 
ELISAs and neutralisation test. TBEV-specific antibodies were detected in 11 of 12 TBE 
vaccinated individuals by rED3-based ELISA (Table 19). One TBE vaccinee was negative by 
rED3-based ELISA, but tested positive by commercial kit. The antibody negative donor was 
also found negative in the ELISPOT (Appendix 2). Interestingly, by neutralisation test in all 
12 serum samples protective neutralizing antibodies were detected with a Geometric mean 
titre (GMT) of 96.04, 95% confident interval (CI): 52.76-174.8. Of the seven TBE 
unimmunized subjects, four of them had a DENV infection in the past and thus containing 
anti-DENV antibodies. These were also tested as control for cross-reactivity between 
flaviviruses. All seven TBE non-vaccinated individuals were negative with both rED3-based 
ELISA and NT while the four DENV sera were positive using commercial ELISA. 
Thus, compared to neutralisation test rED3-based ELISA was shown to have a 
relatively high sensitivity (11/12, 91.6%) and specificity (7/7, 100%). The commercial ELISA 
kit showed a high cross-reactivity with all subjects containing anti-DENV antibodies and 
exhibit a low specificity with 42.8% (3/7) compared to the neutralisation test but has a 
sensitivity of 100% (12/12) (Table 19). These results support the initial results (3.1.) which 
indicated rED3 as a suitable antigen for detection of TBEV specific antibodies. 
Table 19. Comparison between rED3-based ELISA, commercial IgG ELISA kit (recomWell 
FSME/TBE virus IgG), and neutralisation test 
Neutralisation test rED3-based ELISA Commercial ELI SA kit  
 Positive  Negative  Positive  Negative  Total  
Positive  11 1 12 0 12 
Negative  0 7 4 3 7 
Total  11 8 16 3 19 
Sensitiv ity  91.6% 100%  









To find out if there is a correlation between number of specific memory B cells and 
specific plasma antibodies of TBE and Influenza vaccinated individuals a statistic analysis 
was carried out. It showed that there was no significant correlation between serum levels of 
anti-TBEV antibodies and the number of rED3 specific IgG ASCs (p>0.05 r = 0.36). A similar 




Figure 23 . Linear regression and correlation between the frequency of antigen-specific IgG 
ASCs (x-axis) and antigen-specific IgG antibody level in serum (y-axis)  
 
Neutralizing antibody titres were found in all 12 plasma samples obtained from 
vaccinated individuals. In order to appraise the significance of ELISA results for evaluating 
the immune response to TBE vaccination, the correlation was also examined between the 
levels of antibodies as measured by rED3-based ELISA and levels of neutralizing antibodies 
determined by Neutralisation test. Taken together, we observed a good significant correlation 
between IgG antibody detection by TBEV-rED3 based ELISA and neutralizing antibody titres 
obtained by neutralisation test (p< 0.05 and Spearman’s coefficient r = 0.77) (Figure 24). 
Therefore, the level of IgG-antibodies determined by rED3-based ELISA is a good marker for 
predicting the presence of neutralizing antibodies against TBEV. 
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Figure 24. The correlation between neutralizing antibody titres and level of IgG antibodies as OD450 
values. p< 0.05 and Spearman’s coefficient r = 0.77. 
 
As expected the obtained OD values after almost 17 years post-vaccination 
(median=0.189 with a 25% percentile of 0.145, a 75% percentile of 0.789) were significantly 
lower than after 2.5 years post-vaccination (median=0.999 with a 25% percentile of 0.357, a 
75% percentile of 1.327) (Figure 25). But no correlation was also found between neutralizing 
antibody titres and the interval of time since vaccination. No statistically significant influence 
was also observed (Figure 26).  
























Figure 25.  Level of antigen-specific antibodies in TBE vaccinated groups regarded time points of 




































Figure 26.  Correlation of TBE neutralizing antibody titres and years between vaccination and sample 

























CHAPTER 4. DISCUSSION 
 
4.1. Expression and purification of recombinant env elope protein domain 3 (rED3) and 
evaluation of its use for serological TBE diagnosis . 
Currently, antibodies to TBE virus are detected and quantified by ELISA employing 
inactivated whole virus as coating antigen. But due to extensive antigenic cross-reactivity 
serological diagnosis of flavivirus infections is difficult, especially in areas where more than 
one virus type circulates. A situation now exists in Europe, where TBEV and WNV are 
endemic in many countries (Beck et al., 2013). But also the increased mobility of man and 
increased contact of travellers with flaviviruses complicate a specific serological diagnosis. 
Several reports demonstrated that cross-reacting antibodies were present in cases of current 
infection or past vaccination against, other flaviviruses, e.g. West Nile virus, Dengue fever 
virus, Japanese B encephalitis virus, Yellow Fever virus that are detected by ELISA using 
whole virus as antigen (Dobler et al., 1996; Holzmann et al., 1996; Litzba et al., 2013; Niedrig 
et al., 2001). As an alternative antigen, recombinant E protein domain 3 (rED3) is proposed 
as it contains virus-specific epitopes for specific serological diagnostic of flavivirus infection 
(Beasley et al., 2004; Holbrook et al., 2004; Marx et al., 2001). Domain 3 represents the 
receptor-binding domain of the E protein, which is the major flavivirus structural protein and 
antigen (Gritsun et al., 2003; Heinz, 1986; Marsh and Helenius, 1989; McMinn, 1997). 
Antibodies directed against D3 are described as highly neutralizing, whereas antibodies to 
D2 or D1 are cross-reactive (Crill and Chang, 2004; Sukupolvi-Petty et al., 2007).  
In this study TBEV- and WNV-specific antigen ED3 was expressed as MBP fusion 
proteins with C-terminal histidine tag using the bacterial expression system. Using first 
amylose affinity chromatography followed by nickel affinity chromatography highly purified 
rED3 was obtained. Using TBEV-rED3 protein in Western Blot unspecific reaction with serum 
antibodies of negative serum was detected and a differentiation between WNV infection and 
TBEV wasn’t possible. Probably, flavivirus cross-reactive antibodies bind to linear, conserved 
epitopes within ED3 that became accessible due to protein denaturation. Otherwise these 
epitopes are hidden due to the 3D-structure of the protein. This is in contrast to the literature. 
Holbrook and colleagues found that the rabbit anti-TBEV sera did not recognize rED3 
derived from mosquito-borne flaviviruses like WN or YF nor did rabbit anti-YF or anti-WN 
antisera bound to the TBE-rED3 (Holbrook et al., 2004). The findings might be explained by 
the used antisera. The rabbit sera were produced by immunization of rabbit with purified 
rED3 fusion protein, while in this study sera of infected or vaccinated humans was used. 
Additionally, here the rED3 was used as fusion protein with N-terminal MBP moiety. MBP is 
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an important bacterial protein from E. coli for the maltose/maltodextrin metabolism. E. coli is 
a commensal inhabitant of the human intestinal tract. Consequently, anti-MBP reactive 
antibodies were detected in all positive and negative sera.  
When the purified rED3 protein was used as antigen in ELISA TBE virus-specific 
antibodies were detected, only. This demonstrated that rED3 retained sufficient antigenicity 
after purification, which was partly carried out under denaturing conditions. In comparison to 
the commercial ELISA-kit, that uses whole virus as antigen the rED3-based ELISA has 
higher specificity. Cross reactivity of WNV and DENV positive sera was detected in 15 of 18 
sera by commercial IgG ELISA and thus giving a false positive signal. In TBEV-rED3-based 
ELISA, these samples were found negative. Thus, that the TBEV-rED3-based ELISA allows 
a differentiation of infections caused by TBE serogroup and mosquito-borne flaviviruses but 
not the inactivated whole virus based commercial ELISA. The antigen used might explain 
this. In the whole virus preparation the complete E-protein is present and thus none 
neutralizing but highly cross reactive antibodies i.e. D2 specific antibodies can bind and give 
a positive signal. Using correctly folded ED3 allows only the binding of specific antibodies as 
it was described in literature that ED3 induces specific neutralizing antibodies (Crill and 
Chang, 2004; Sukupolvi-Petty et al., 2007). These results were in agreement with previous 
studies on the use of rED3 as antigen in ELISA. WNV-rED3 for example was found superior 
to whole virus antigens as it allowed discrimination between WNV and other flavivirus 
infection, such as St. Louis encephalitis virus (SLEV), Japanese encephalitis virus (JEV) and 
Murray Valley encephalitis virus (MVEV) (Beasley et al., 2004). Another study described the 
development of a diagnostic ELISA for JEV infections using JEV-D3 peptide antigen, which 
showed 98% sensitivity and 96% specificity when compared to a commercial ELISA (Shukla 
et al., 2009). Recombinant DENV-D3 was also a reliable antigen for ELISA in order to 
identify the DENV serotypes in primary infection (Wahala et al., 2009). TBEV-rED3 did not 
allow differentiation of very similar TBE viruses but it was highly specific for the tick-borne 
flaviviruses and allowed differentiation of TBE serocomplex flaviviruses from mosquito-borne 
flaviviruses in ELISA (Holbrook et al., 2004). 
Noticeably are the obtained lower OD450 values by ELISA on TBEV-rED3. Similar 
results were found for DENV, where only low amounts of serum antibodies were directed 
against rED3 (Wahala et al., 2009). This might be explained by the fact that in humans only 
the minority of produced antibodies are directed against ED3 as shown for WNV-antibodies 
(Throsby et al., 2006).  
In our study, the specificity of rED3 based ELISA obtained 100%, sensitivity was only 
91.6% when compared to neutralisation test as the most specific test. One vaccinee was 
negative by rED3-based ELISA, but positive by commercial IgG ELISA and neutralisation 
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test. This finding is consistent with previous data on human immune responses, which 
showed that after vaccination or infection not all individuals generate a significant IgG 
antibody response against the ED3 epitope (Oliphant et al., 2007). A large fraction of the 
E-specific antibodies was directed against ED2 epitope, but ED2 specific neutralizing 
antibodies were less potent as mAbs that bound to ED2 protected only 18–60% of mice 
when given two days after infection with WNV compared to ED3 specific mAbs, which 
protected 80–100% of mice (Oliphant et al., 2006). Nevertheless, ED3-responses formed 
only a very small proportion of the total antibody response (Throsby et al., 2006; Vratskikh et 
al., 2013; Wahala et al., 2009).  
This study also showed that all TBE vaccinated individuals presented the protective 
neutralizing antibodies as quantified by neutralisation test. Neutralizing antibodies have been 
maintained for a long time since last vaccination. This is in line with previous observations 
that neutralizing antibodies are likely to remain at a sustainable “plateau” titre following three 
doses of primary immunization without any apparent dependency on elapsed time since last 
immunization (Rendi-Wagner et al., 2007; Schosser et al., 2009). Additionally, the 
quantitative determination of specific IgG in TBE post-vaccination sera by rED3-based ELISA 
exhibits a good correlation with neutralizing antibodies titres. This may be due to the fact that 
the rED3-based ELISA antigen is employed which represents the primary target for 
neutralizing antibodies. The presence of specific antibodies in this ELISA is therefore highly 
predictive for the presence of neutralizing antibodies, and this correlation can probably be 
used in the future to establish guidelines for recommendations of booster vaccinations 
(Holzmann et al., 1996; Rendi-Wagner et al., 2004). 
Altogether, the results demonstrate clearly that production of a highly antigenic 
protein using the bacterial expression system is a promising alternative to the conventional 
production of viral proteins by inactivation of whole virus. The bacterial expression system 
assures correct protein processing and folding, two important criteria for the preservation of 
conformational antigenic epitopes. Such recombinant flavivirus specific proteins represent 






4.2. Establishment of a memory B cells assay using rED3 as antigen for determination 
of frequency of rED3 specific antibody-secreting ce lls (ASCs) in individuals 
vaccinated against TBE.  
Nowadays, common vaccination recommendations often take into account only the 
antibody titre as a criterion for vaccinations and as an indicator of immunological memory. 
Long-lived plasma cells (LLPCs) in bone marrow secrete antibodies over a long time to 
maintain titre but nonetheless levels decline gradually (Ahuja et al., 2008; Manz et al., 1997). 
But vaccine induced immunological memory is not only based on serum antibody titers. It is 
also based on memory B cells, which are present for years but don’t produce antibodies 
before re-encounter their specific antigen (Amanna and Slifka, 2010). Thus, long-term effect 
of vaccination is showing on the frequency of antigen-specific B cells and the level of the 
antibody titre in the serum (Zinkernagel et al., 1996). It would be desirable for modern 
vaccine strategies to be based, increasingly, to the memory B cells as a parameter for 
long-term immunity.  
Various methods have previously been described for inducing the differentiation of 
human memory B cells. These methods involve the culture of peripheral blood mononuclear 
cells (PBMCs) or purified B cells for 5 to 6 days in the presence of polyclonal stimuli and 
cytokines, such as ConA with IL-2, IL-4, IL-6 (Slifka and Ahmed, 1996); pokeweed mitogen 
(PWM) with Staphylococcus aureus Cowan I (SAC) (Munoz and Insel, 1987); SAC and 
interleukin (IL)-2 (Kelly et al., 2006); PWM, unmethylated CpG oligodeoxynucleotides (CpG 
ODN) and SAC (Crotty et al., 2004); CD40L transfected CDw32L mouse fibroblasts plus IL-2 
and IL-10 (Tuaillon et al., 2006); CpG and IL-15 (Bernasconi et al., 2002); 
PWM, Staphylococcus aureus lysate, IL-2, IL-10 and phosphorothioated CpG ODN 
(Bussmann et al., 2010); TLR7/TLR8 agonist R848 plus IL-2 (Jahnmatz et al., 2013; Pinna et 
al., 2009; Walsh et al., 2013). 
Here, an ELISPOT protocol previously optimized by Jahnmatz et al. for the analysis 
of vaccine-induced B-cell responses (Jahnmatz et al., 2103) was used in order to determine 
the numbers of ASCs produced by individuals who got vaccinated against TBE. Memory B 
cells activated with R848 (Resiquimod) and rhIL-2 indicated to be significantly better than 
PWM used in combination with various co-activators (Jahnmatz et al., 2013; Pinna et al., 
2009; Walsh et al., 2013). In this study, stimulation with R848 and IL-2, TBEV-rED3 specific 
ASCs could be detected in 11 of 12 TBE vaccinated individuals; even anti-TBE antibodies 
levels were low in serum. Our finding was in agreement with previous observations indicated 
that HBs-ASCs were also detected in HBV immunized individuals with serum anti-HBs 
antibodies under protective level. But HBs-specific memory B cells could rapidly differentiate 
into plasma cells after re-encounter with HBV antigen and rule out infection of hepatitis B by 
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secreted antibodies (Margolis, 1993; Tuaillon et al., 2006; West and Calandra, 1996). Only 
one individual who received two instead of three primary doses of TBE vaccine no TBEV-
rED3 specific memory B cells were detected; though, had protective neutralizing antibodies 
against TBE. This is explained that antigen specific memory B cells in this person may be at 
low frequency and below the limit of detection of assay. Previously, Buisman and colleagues 
also demonstrated that ELISPOT using PBMCs were able to identify specific memory B cells, 
but only when a minimal frequency of these cells was present in blood (Buisman et al., 
2009).  
In this study, frequency of antigen specific memory B cells was between 0.016% and 
0.188% for TBE, 0.012% and 0.51% for Influenza per total IgG ASCs. The results were in 
accordance with previous reports on circulating memory B cell specific to tetanus toxoid (TT) 
(0.02-0.87%) (Bernasconi et al., 2002; Buisman et al., 2009), smallpox (0.1%) (Crotty et al., 
2003), anthrax (0.05-2%) (Crotty et al., 2004), or HBV (0.02-0.58%) (Tuaillon et al., 2006). 
We have shown that TBE-specific memory B cells could be maintained for more than 20 
years of post-vaccination. In this study, there was a significant difference in number of ASCs 
between vaccinated and non-vaccinated group (p<0.05). Interestingly, there was no evidence 
showing a significant difference between TBE vaccinated groups within 1-5 years (mean of 
2.5 years) and >10 years (mean of 16.5 years) of post-vaccination (p>0.05). Our results were 
in agreement with other studies demonstrating that the immunological memory as 
antigen-specific memory B cells in humans may be maintained for many years (Buisman et 
al., 2009; Migot et al, 1995; West and Calandra, 1996), even for more than 50 years (Crotty 
et al., 2003), while antibody titres often decrease after the last exposure to the antigen 
(Ahmed and Gray, 1996; Simonsen et al., 1984). These findings also proved that memory B 
cell numbers were stable for years (Crotty et al., 2003; Schittek and Rajewsky, 1990).  
No significant correlation was found between the number of circulating 
antigen-specific memory B-cells and serum level of antigen-specific IgG for both TBE and 
Influenza. This observation is in agreement with previously published data (Bernasconi et al., 
2002; Bocher et al., 1996; Crotty and Ahmed, 2004; Lanzavecchia, 1983; Leyendeckers et 
al., 1999; Nanan et al., 2001; Rojas et al., 2008; Slifka et al., 1998; Tuaillon et al., 2006). It 
revealed that memory B cells and plasma cells participate as independently controlled forms 
of immunological memory (Leyendeckers et al., 1999; Rosado et al., 2011) and LLPCs in 
bone marrow are an important source in maintaining serological memory (levels of specific 
serum Ig) (Rojas et al., 2008). Memory B cells on the other hand seem to play a major role in 
antigen processing and presentation, and act as precursors for the rapid antibody-secreting 
response after antigen re-exposures as well as promptly differentiating in plasma cells 
(Bachmann and Koft, 1999; Elkins et at., 1999; Slifka et al., 1998). However, previous reports 
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indicated a significant correlation between serum antibody titres and smallpox-specific 
memory B cells as well as the frequency of measles or tetanus toxin-specific memory B cells 
and the serum antibody titre, and demonstrated that many factors involved in the relationship 
between memory B cell levels and circulating antibody levels (Crotty et al., 2003; 
Lanzavecchia et al., 2006). 
 The mechanisms for the longevity of memory B cells are controversial (Ahmed and 
Gray, 1996; Mamani-Matsuda et al., 2008; Maruyama et al., 2000; Yoshida et al., 2010). 
Many authors have demonstrated that memory B cells and LLPCs are exclusively 
antigen-dependent (Benson et al., 2009; Maruyama et al., 2000). However, it has been 
proposed that after the generation of memory B cells, they are maintained by periodic re-
encounter with antigen presented long-term by follicular dendritic cells (FDCs) (Amanna and 
Slifka, 2010; Fishman and Perelson, 1995; Gray et al, 1996; MacLennan, 1994). The 
follicular dendritic cells of germinal centres play an important role in antigen presentation. 
However, retention of antigen by FDCs only persists for weeks to months (Mandel et al., 
1980). For re-encounter of memory B cells with antigen other forms of antigen could be 
persistent at low levels or memory B cells are stimulated by cross reactive environment or 
self-antigen (Amanna et al., 2006; Gray et al., 1996; Zinkernagel et al., 1996).  
Schittek and Rajewsky (1990) showed in a mouse model that memory B cells could 
survive in a non-proliferative state for several weeks or they only do decline at rate that may 
be too slow to be measured by current methods (reviewed in Amanna et al., 2006). Another 
hypothesis assumes that the maintenance of human memory B cells is a bystander 
polyclonal activation. As memory B cells were stimulated in vitro with Toll-like receptors 
(TLRs) or polyclonal activators they will undergo several rounds of proliferation and 
differentiation into plasma cells, but not naïve B cell (Bernasconi et al., 2003; Crompton et 
al., 2009; Kasturi et al., 2011). More recently, Komegae et al. indicated that TLRs and 
myeloid differentiation primary response gene-88 (MyD88) signaling play an important role in 
longevity of memory B cells and LLPCs (Komegae et al., 2013). 
B cells within the different memory populations may have different intrinsic 
requirements for their survival related to their exposure to antigen (acute, chronic or recurrent 
infection). Therefore, fundamental differences in memory B cell populations depend on the 
pathogen that is partly responsible for some vaccines requiring boosters, and others 
generating lifelong immunity (Tarlinton and Good-Jacobson, 2013).  
 At the molecular level, the longevity of the memory B cells was regulated by 
expression of the anti-apoptotic gene Bcl-2. Transgenic mice overproducing Bcl-2 lead to an 
extended lifetime for memory B cells (Nunez et al., 1991; Smith et al., 1994). Dogan et al. 
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showed the survival and function of memory B cells on the existence of multiple layers of B 
cell memory, antigen-dependent and independent and effector functions (Dogan et al., 2009)  
Human vaccines induce serum antibody responses that maintain for many years, 
even for decades as vaccines against smallpox and Yellow fever, and therefore 
vaccine-specific plasma cells must be present for decades (Amanna et al., 2006). Previously, 
it was assumed that half-life of short-lived plasma cells were a few days to a few weeks 
(Shapiro-Shelef and Calame, 2005). Thus, antibody production is maintained by LLPCs with 
their persistence for years in bone marrow and spleen after vaccination (Good-Jacobson and 
Tarlinton, 2012; Manz et al., 1997; Slifka et al., 1998). Another possibility is that serum 
antibodies may be maintained by memory B cells as a positive correlation between serum 
antibody levels and antigen-specific memory B cells was observed (Crotty et al., 2003; 
Lanzavecchia et al., 2006). However, many other studies found no correlation between 
serum antibody titres and antigen-specific memory B cell frequency (Ahuja et al., 2007; 
Bocher et al., 1996; Crotty and Ahmed, 2004; Lanzavecchia, 1983; Leyendeckers et al., 
1999; Nanan et al., 2001; Rojas et al., 2008; Slifka et al., 1998; Tuaillon et al., 2006). Our 
results are in agreement with these findings that antibody production is independent with the 
presence of memory B cells.  
Antigen-specific memory B cells play an important role for the long-term immunity. 
This study showed that the number the previous booster vaccinations correlated strongly 
with the frequency of circulating memory B cells. This suggests that the circulating memory B 
cells better reflect immunological long-term memory induced by booster immunizations than 
the amount of the antibody titre. Thus, memory B cells seem to be a far more important 
parameter for the assessment of long-term immunity.  
Our data show that individuals who only got the unique booster increase the specific 
antibody titre and antigen-specific memory B cell frequency. Looking at the relationship 
between the time since immunization with last dose and frequency of antigen-specific 
memory B cells, it is clear that even 10-25 years after vaccination the specific memory B 
cells are still maintained for protection from disease infection.  
In summary, we have found the ELISPOT is a suitable method for detecting TBE 
antigen-specific memory B cells in individuals who have been previously vaccinated. This 
study provides data on immunological memory following TBE vaccination; it is useful for the 







Tick-borne encephalitis virus (TBEV) is a serious viral infection that affects the central 
nervous system. It was estimated that between 1990 and 2009 a total of 169,937 cases of 
TBE were recorded in Europe. TBEV belongs to genus Flavivirus that comprises over 70 
viruses, many of them are important human pathogens. Most members are either transmitted 
by mosquitoes e.g. West Nile virus (WNV), Dengue virus (DENV) or ticks e.g. TBEV. Due to 
the extensive antigenic cross-reactivity among flaviviruses serological diagnosis of TBE 
infections is commonly difficult in areas where more than one virus type circulates. 
Particularly, a situation now exists in Europe, where TBEV and WNV are endemic in many 
countries Thus, this thesis focused on the one hand on optimization of serological test 
systems using recombinant envelope protein domain III (rED3). It represents domain 3 of the 
major antigen, the surface protein E, which additionally has been shown to induce flavivirus 
specific neutralizing antibodies. Therefore rED3 was expressed and purified and its 
application as antigen in ELISA for TBEV diagnosis was verified.  
On the other hand a memory B-cell assay was established to analyse antiviral immunity after 
TBEV-vaccination. Here rED3 was used as antigen to determine the frequency of rED3 
specific antibody-secreting cells (ASCs). Vaccination is the most effective method of 
preventing TBE disease and is currently recommended for all those who live and work or 
travel to areas of TBE endemicity. An essential requirement of any vaccine is the induction of 
long-term protective immunity. Several vaccines have defined levels of serum antibody (as 
measured by ELISA, haemagglutination inhibition test, or neutralisation test) that serve as 
correlates or surrogates of protective immunity. But this does not take account of 
vaccine-induced memory B cells. Although, not providing direct protection against infection, 
they represent an important second line of immune defence that is initiated only if 
pre-existing antibody levels are too low to prevent infection or if the invading pathogen is able 
to circumvent the pre-existing antibody response. A thorough understanding of the 
frequencies of antigen-specific memory B cells and their relationship with the antibodies in 
serum serological memory is likely to be critical to give information about the long-term 
efficacy of vaccine as well as its correlates of protection. 
This thesis focuses on the establishment of a recombinant protein based ELISA and of a 
memory B cell assay for analysis of specific antiviral immunity after vaccination with the 
following two objectives: (1) Expression and purification of recombinant envelope protein 
domain 3 (rED3) and verification of its application as antigen in ELISA for TBEV diagnosis; 
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(2) Establishment of a memory B cells assay using rED3 for determination of frequency of 
rED3 specific antibody-secreting cells (ASCs) in individuals vaccinated against TBE. 
In this study, TBEV- and WNV-specific antigen ED3 was expressed in E. coli as MBP fusion 
proteins with C-terminal histidine tag using pMAL-c2x vector. By purification with amylose 
affinity chromatography followed by nickel affinity chromatography, highly purified 
TBEV-rED3 and WNV-rED3 were obtained. Nevertheless, using TBEV-rED3 protein in 
Western Blot unspecific reaction with serum antibodies of negative serum was detected and 
a differentiation between WNV infection and TBEV was impossible, probably due to the MBP 
moiety. 
However, using the purified rED3 protein as antigen in ELISA, TBE virus-specific antibodies 
were detected specifically. Twenty-three serum samples predefined as TBEV positive were 
tested positive by rED3-based ELISA and commercial IgG ELISA. Five predefined negative 
serum samples were tested negative by rED3-based IgG ELISA as well as commercial 
IgG-ELISA. But cross reactivity of WNV and DENV positive sera was detected in 15 of 18 
sera by commercial ELISA. On the other hand, these samples were found negative in 
TBEV-rED3-based ELISA. Thus, TBEV-rED3-based ELISA allows a differentiation of 
infections caused by TBE serogroup and mosquito-borne flaviviruses but not the inactivated 
virus based commercial ELISA. Interestingly, compared to neutralisation test the specificity of 
rED3-based ELISA obtained 100% with a sensitivity of 91.6%. In contrast, the commercial 
ELISA obtained 100 % sensitivity but a low specificity with only 42.8%. 
In order to determine frequency of antigen-specific antibody secreting cells (ASCs) produced 
by individuals who received the vaccination against TBE, peripheral blood mononuclear cells 
(PBMCs) were isolated from blood samples. Subsequently, memory B cells were activated 
with R848 (Resiquimod) and human recombinant IL-2 (hrIL-2) for 72 hours in 37°C, 5% CO2, 
90% humidity. After 72 hours of incubation, Enzyme-Linked Immunospot (ELISPOT) 
detected antigen-specific memory B cells. In order to evaluate specificity of TBEV-rED3 in 
ELISPOT, other antigens including WNV-rED3, Maltose binding protein (MBP) and Influenza 
Nucleoprotein (NP) were included. Study subjects could be separated into two groups: last 
vaccination before 5 years or longer than 10 years. TBEV-rED3 specific ASCs could be 
detected in 11 of 12 TBE vaccinated individuals with different vaccination history and even 
low serum anti-TBE antibodies levels. TBEV-rED3 specific ASCs were found with frequency 
of ranging 0.016-0.188 % per total IgG ASCs and lower than frequency of Influenza-NP 
specific ASCs (between 0.012-0.51%). But TBE-specific memory B cells could be maintained 
for more than 20 years of post-vaccination. There was a significant difference in number of 
ASCs between vaccinated and non-vaccinated group (p<0.05). Interestingly, there was no 
significant difference between TBE vaccinated groups between 1-5 years (mean of 2.5 
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years) and >10 years (mean of 16.5 years) since vaccination (p>0.05). These finding proved 
that memory B cells have been stable for years and are maintained up to 25 years since last 
vaccination. 
A statistic analysis showed that there was no significant correlation between serum levels of 
anti-TBEV antibodies and the frequency of rED3 specific IgG ASCs (p>0.05, Spearman’s 
coefficient r = 0.36). A similar result was also indicated for influenza-vaccinated individuals 
(p>0.05, Spearman’s coefficient r = 0.27). These findings revealed that memory B cells and 
plasma cells maybe play an independently role in maintaining of immunological memory. 
Anyway, neutralizing antibodies have been found in all vaccines (a Geometric mean titre 
(GMT) of 96.04, 95% confident interval (CI): 52.76-174.8) and thus were maintained for a 
long time since last vaccination. Interestingly, the quantitative determination of specific IgG in 
TBE post-vaccination sera by rED3-based ELISA exhibits a good correlation with neutralizing 
antibody titres. The presence of specific antibodies in rED3-based ELISA is therefore highly 
predictive for the presence of neutralizing antibodies, and this correlation can probably be 
used in the future to establish guidelines for recommendations of booster vaccinations. 
Additionally, it became apparent that the number of previous booster vaccinations correlated 
strongly with the frequency of circulating memory B cells. As expected, individuals who 
received a booster increased both the specific antibody titre and frequency of 
antigen-specific memory B cells. This suggests that immunological long-term memory 
induced by booster immunizations is better reflected by the circulating memory B cells than 
the amount of the antibody titre. Thus, memory B cells seem to be a more reliable parameter 
for the assessment of long-term immunity. 
Taken together, a highly antigenic rED3 using the bacterial expression system was produced 
and it is a promising alternative to whole inactivated virus in ELISA. Notably, rED3 was a 
reliable antigen for detecting antigen-specific memory B cells in individuals who have been 
previously TBEV vaccinated. This study provides data on immunological memory for TBE 
vaccination and might be useful for reconsideration of recommendations for booster dose.  
In conclusion, boosters of vaccination should be recommended for all individuals who live 
and work or travel to areas of TBE endemicity. As consequently, vaccine-induced protection 
is enhanced by both strong humoral and cell-mediated immune responses. If pace of 
pathogenesis is rapidly growing, pre-existing virus-specific antibodies represent the first line 
of defence against infection before the memory response is fully activated and implemented. 
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ASCs/10 6 PBMCs 
Inactivated TBEV 
specific ASCs/10 6 
PBMCs 
TBE vaccinated 
< 5 years 
1 99 000 50 0.05 70 0.07 0 0 
2 20 000 5 0.025 42 0.21 0 0 
3 29 250 22 0.075 37 0.12 0 0 
4 13 250 25 0.188 10 0.075 0 0 
5 16 500 11 0.066 2 0.012 0 0 
6 31 000 5 0.016 32 0.103 0 0 
>10 years 
7 15 250 10 0.065 64 0.42 0 0 
8 35 000 10 0.028 60 0.17 0 0 
9 71 000 0 0 34 0.048 0 0 
10 10 750 5 0.046 7 0.065 0 0 
11 19 000 10 0.05 0 0 0 0 
12 15 250 15 0.098 78 0.51 0 0 
TBE non-
vaccinated 
Without infection of any flavivirus  
13 28 500 0 0 66 0.230 0 0 
14 23 000 0 0 20 0.087 0 0 
15 10 500 0 0 11 0.105 0 0 
DENV infected 
16 18 500 0 0 20 0.108 0 0 
17 21 500 0 0 5 0.023 0 0 
18 22 000 0 0 28 0.13 0 0 
19 16 750 0 0 46 0.27 0 0 
 



















< 5 years  
 
1 0.05 1.092 161.094 112 
2 0.025 0.418 91.073 35 
3 0.075 1.362 187.882 234 
4 0.188 0.906 180.976 355 
5 0.066 0.175 34.618 35 
6 0.016 1.314 190.172 282 
> 10 years  
 
7 0.065 0.792 146.290 178 
8 0.028 0.208 59.275 28 
9 0 0.076 25.084 35 
10 0.046 0.171 78.711 177 
11 0.05 0.168 44.555 44 




Never infected by any flavivirus  
 
13 0 0.062 2.1810 <10 
14 0 0.032 0.934 <10 
15 0 0.037 0.901 <10 
DENV infected  
 
16 0 0.016 132.412 <10 
17 0 0.027 47.056 <10 
18 0 0.010 48.741 <10 
19 0 0.017 64.033 <10 
 
a: samples are determined positive if OD450  value of sample > 0.146 (cutoff) 
b: Samples are positive if ELISA index value >24 U/ml (cutoff)  
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